




















e structural variation m
odulating the placenta and pregnancy m
aintenance
LAURA KASAK
Genome structural variation modulating 
the placenta and pregnancy maintenance 
 

























Genome structural variation modulating  
the placenta and pregnancy maintenance  
Institute of Molecular and Cell Biology, University of Tartu, Estonia 
Dissertation was accepted for the commencement of the degree of Doctor of 
Philosophy in Gene Technology on March 8th, 2018 by the Council of the 
Institute of Molecular and Cell Biology, Faculty of Science and Technology, 
University of Tartu. 
 
Supervisor:  Prof. Maris Laan, PhD 
Institute of Biomedicine and Translational Medicine 
University of Tartu 
Estonia 
 
Opponent:  Prof. Julie C. Baker, PhD 




Commencement: Room No 105, 23B Riia St., Tartu, on May 22nd, 2018, 
at 12:15. 
 
Publication of this thesis is granted by the Institute of Molecular and Cell 















ISBN 978-9949-77-705-1 (print)  
ISBN 978-9949-77-706-8 (pdf)  
 
Copyright: Laura Kasak, 2018 
 
 
University of Tartu Press  
www.tyk.ee    
5 
TABLE OF CONTENTS 
LIST OF ORIGINAL PUBLICATIONS  ......................................................  7 
LIST OF ABBREVIATIONS  .......................................................................  8 
INTRODUCTION  .........................................................................................  11 
1. REVIEW OF LITERATURE  ...................................................................  13 
1.1  Biology of pregnancy maintenance  ..................................................  13 
1.1.1  Implantation in human  ...........................................................  14 
1.2  Placenta as a key organ for pregnancy success  ................................  15 
1.2.1  Placental development and function at the fetal maternal 
interface  ..................................................................................  15 
1.2.2  Placenta as a unique mammalian organ  .................................  17 
1.2.3  Mosaicism in the human placenta  ..........................................  17 
1.3  Recurrent pregnancy loss ..................................................................  18 
1.3.1  Known causes of RPL  ............................................................  18 
1.3.2  Genetic factors causing RPL (also reviewed in Ref. IV)  .......  20 
1.4  Late pregnancy complications  ..........................................................  21 
1.4.1  Preeclampsia ...........................................................................  21 
1.4.2  Gestational diabetes mellitus  ..................................................  23 
1.4.3  Fetal growth abnormalities  .....................................................  23 
1.5  Structural variation in the human genome  ........................................  24 
1.5.1  DNA copy number variation  ..................................................  25 
1.5.2  CNV detection methods  .........................................................  26 
1.5.3  CNVs in pregnancy complications  .........................................  28 
2. AIMS OF THE STUDY  ...........................................................................  31 
3. RESULTS AND DISCUSSION  ..............................................................  32 
3.1  DNA copy number variation in recurrent pregnancy loss parental 
genomes (Ref. I, III)  .........................................................................  32 
3.1.1  Study design  ...........................................................................  32 
3.1.2  Increased burden of CNVs in the genomes of RPL patients  ..  33 
3.1.3  Experimental validation and replication of recurrent CNVs  ..  35 
3.1.4  Genomic context of the PDZD2:GOLPH3 duplication and 
expression profile of the disrupted genes  ...............................  38 
3.1.5  Major contribution of this study to the field of RPL research   40 
3.2  Submicroscopic genomic rearrangements in the placental and 
parental genomes of normal and complicated pregnancies (Ref. II)   40 
3.2.1  Study design  ...........................................................................  40 
3.2.2  Extensive load of CNVs in the placental genomes  ................  41 
3.2.3  Profile of inherited and somatic placental CNVs  ...................  42 
3.2.4  Enrichment of imprinted genes in somatic duplications  ........  45 
3.2.5  Reduced amount of somatic duplications in late pregnancy 
complications  .........................................................................  47 
3.2.6  Older mothers have reduced amount of placental CNVs  .......  48 
6 
3.2.7  Major contribution of this study to the field of placental 
research  ..................................................................................  49 
3.3  DNA copy number variation in recurrent pregnancy loss placental 
genomes (Ref. III)  ............................................................................  49 
3.3.1  Reduced amount of rearrangements and low fraction of 
shared CNVs in the placental samples of RPL cases 
compared to normal pregnancy  ..............................................  50 
3.3.2  Functional pathway analysis of placental CNVRs specific to 
RPL cases and controls  ..........................................................  51 
3.3.3  A closer look at the parental and placental CNV profiles of 
the three live birth RPL cases  .................................................  53 
3.3.4  Major contribution of this study to the field of placental and 
RPL research  ..........................................................................  53 
4. EXTENDED DISCUSSION AND FUTURE PERSPECTIVES  ..............  54 
4.1  Load of structural variants in the placenta – harm or benefit?  .........  54 
4.2  Placental CNVs and non-invasive prenatal testing  ...........................  55 
4.3  Importance of CNV profiling in the clinical management of 
pregnancy complications  ..................................................................  56 
5. CONCLUSIONS  .......................................................................................  58 
REFERENCES  ..............................................................................................  59 
SUMMARY IN ESTONIAN  ........................................................................  71 
ACKNOWLEDGEMENTS  ..........................................................................  74 
PUBLICATIONS  ..........................................................................................  75 
CURRICULUM VITAE  ...............................................................................  159 
ELULOOKIRJELDUS  ..................................................................................  162 
  
7 
LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following original articles and a book chapter 
referred to in the text by their Roman numerals: 
I Nagirnaja, L; Palta, P; Kasak, L; Rull, K; Christiansen, O B; Nielsen, H 
S; Steffensen, R; Esko, T; Remm, M; Laan, M. 2014. Structural genomic 
variation as risk factor for idiopathic recurrent miscarriage. Human 
Mutation, 35 (8), 972–982. 
II Kasak, L; Rull, K; Vaas, P; Teesalu, P; Laan, M. 2015. Extensive load of 
somatic CNVs in the human placenta. Scientific Reports, 5 (8342), 1–10. 
III Kasak, L; Rull, K; Sõber, S; Laan, M. 2017. Copy number variation 
profile in the placental and parental genomes of recurrent pregnancy loss 
families. Scientific Reports, 7 (45327), 1–12. 
IV Kasak, L; Rull, K; Laan, M. Genetics and Genomics of Recurrent 
Pregnancy Loss. In: Leung, P and Qiao, J, editors. Human Reproductive 
and Prenatal Genetics. Elsevier Inc.; November 2018 (Invited book 
chapter, in press).  
Articles are reprinted with the permission of copyright owners. 
Author’s contribution 
Ref. I ‒ carried out majority of the experiments, participated in data analysis 
and interpretation and contributed to manuscript preparation 
Ref. II, III ‒ contributed as the leading researcher, participated in experimental 
design, data analysis and interpretation, wrote the first draft of the paper 
Ref. IV – contributed to the preparation of the book chapter  
8 
LIST OF ABBREVIATIONS 
ACAP3 ArfGAP with coiled-coil, ankyrin repeat and PH 
domains 3 
aCGH   array comparative genomic hybridization 
ALDH1L1  aldehyde dehydrogenase 1 family member L1 
aPL    antiphospholipid antibody 
APS    antiphospholipid antibody syndrome 
BAF   B-allele frequency 
bp   base pair 
BMI   body mass index 
BP   breakpoint 
C4A    complement C4A (Rodgers blood group) 
C4B    complement C4B (Chido blood group) 
CDH19   cadherin 19 
CEA   carcinoembryonic antigen 
CGB   chorionic gonadotropin beta subunit 
GCH1   GTP cyclohydrolase 1 
CLEC   C-type lectin domain family 
CN   copy number 
CNV   copy number variation 
CNVR   copy number variation region 
COL11A1  collagen type XI alpha 1 chain 
CPSF3L alias INTS11  integrator complex subunit 11 
CPXM2  carboxypeptidase X, M14 family member 2 
CSMD3  CUB and Sushi multiple domains 3 
CTNNA3   catenin alpha 3 
CTS   cathepsins 
CYP   cytochrome P450 family  
DECIPHER  DatabasE of genomiC varIation and Phenotype in 
Humans using Ensembl Resources 
DGV   Database of Genomic Variants  
DKK2   Dickkopf 2 homolog  
DNA    deoxyribonucleic acid 
DPYD    dihydropyrimidine dehydrogenase 
DVL1   dishevelled segment polarity protein 1 
E2F   transcription factor E2F family 
EPHA7   ephrin receptor A7 
ESHRE European Society of Human Reproduction and 
Embryology 
FII    coagulation factor II, thrombin 
FV    coagulation factor V 
FFPE   formalin-fixed paraffin-embedded 
FGFRL1  fibroblast growth factor receptor like 1 
9 
FISH   fluorescence in situ hybridization 
GDM   gestational diabetes mellitus 
GKLF alias KLF4 Kruppel like factor 4 
GLTPD1  ceramide-1-phosphate transfer protein 
GOLPH3  golgi phosphoprotein 3 
GRIK2   glutamate ionotropic receptor kainate type subunit 2 
GWAS   genome-wide association study 
HLA   human leukocyte antigen 
HOXA   homeobox A cluster 
HOXC   homeobox C cluster 
ICM    inner cell mass 
IFNG    interferon gamma 
IGF2   insulin like growth factor 2 
IGF2R   insulin like growth factor 2 receptor 
IGH   immunoglobulin heavy locus 
IGHA2   immunoglobulin heavy constant alpha 2 
IGHE    immunoglobulin heavy constant epsilon 
IGHG   immunoglobulin gamma heavy chain  
IGKV   immunoglobulin kappa variable cluster 
IL    interleukin 
IUGR   intrauterine growth restriction 
IVF   in vitro fertilization 
kb   kilobase 
KCNQ1  potassium voltage-gated channel subfamily Q member1 
KCNQ1OT1  KCNQ1 opposite strand/antisense transcript 1 
LEP   leptin  
LGA   large-for-gestational age 
LHB   luteinizing hormone beta polypeptide 
LRP2   low-density-lipoprotein-receptor-related protein 2 
LRR   log R ratio 
Mb   mega base 
MLPA   multiplex ligation-dependent probe amplification 
mRNA   messenger ribonucleic acid 
MSR1   macrophage scavenger receptor 1 
MTHFR   methylenetetrahydrofolate reductase 
mTOR   mammalian target of rapamycin 
MTRR   methionine synthase reductase 
NGS   next generation sequencing 
NK   natural killer 
NOS3   nitric oxide synthase 3 
NTM   neurotrimin 
OR   odds ratio 
PDZD2   PDZ domain containing 2 
PE   preeclampsia 
PEG1 alias MEST mesoderm specific transcript 
10 
PEX10   peroxisomal biogenesis factor 10 
PGD    preimplantation genetic diagnosis 
PHLDA2  pleckstrin homology like domain family A member 2 
PKP3   plakophilin 3 
PRDM16  PR/SET domain 16 
PSG   pregnancy specific glycoprotein 
PUSL1   pseudouridylate synthase-like 1 
qPCR   quantitative polymerase chain reaction 
RPL   recurrent pregnancy loss 
SAM   S-Adenosyl methionine 
SCNN1D   sodium channel epithelial 1 delta subunit 
SEPT14  septin 14 
sFlt-1   soluble fms-like tyrosine kinase 1  
SGA   small-for-gestational age 
SLC22A3  solute carrier family 22 member 3 
SNP   single nucleotide polymorphism 
SNV   single nucleotide variant 
SREBP-2  sterol regulatory element binding transcription factor 2 
SOHLH1  spermatogenesis and oogenesis specific basic helix-
loop-helix 1 
TAS1R3  taste 1 receptor member 3 
TFAP2A  transcription factor AP-2 alpha 
TGC   trophoblast gigant cell 
TIMP2   TIMP metallopeptidase inhibitor 2 
TMEM203  transmembrane protein 203 
TNF   tumor necrosis factor 
TP   tumor protein 
VEGFA  vascular endothelial growth factor A 
VWF   von Willebrand factor 
WDR27  WD repeat domain 27 
WES   whole-exome sequencing 
WGS   whole-genome sequencing 
ZF5 alias ZBTB14 zinc finger and BTB domain containing 14 
 
    
11 
INTRODUCTION 
The establishment and maintenance of pregnancy relies on the well-coordinated 
crosstalk between the mother and the embryo. Human reproduction has very 
low efficiency with 30% of all conceptions failing already before implantation. 
Another 40% result in miscarriage, the most prevalent human gestational 
complication. Recurrent pregnancy loss (RPL), defined as ≥3 consecutive losses 
before gestational week 24, affects 1–2% of couples trying to conceive. RPL is 
known for its multifactorial etiology; however, 25–50% of all cases are still 
reported as idiopathic. 
Pregnancy is an enormous physiological challenge a woman can experience 
and can temporarily expose subclinical diseases that will reoccur later in life. 
For some women, the physiological adaptations during pregnancy cause late 
gestational complications, including preeclampsia (PE), gestational diabetes 
mellitus (GDM) and fetal growth abnormalities, which can lead to chronic 
physiological outcomes for the mother. Additionally, children born from 
complicated pregnancies may also have an increased risk of different diseases 
throughout life. As these gestational complications affecting women and their 
offspring all over the world are often associated with poor trophoblast invasion 
and placental function, there is an urgent need for better understanding of pla-
cental biology, development and function. Placenta, the only transient organ in 
the body, mediates all interactions between the mother and the baby, but often 
remains under-investigated due to complex sample collection procedures 
(sampling, storage, accompanying clinical information) and ethical restrictions. 
Placental gene expression levels and dynamics regulate the function of placenta 
and therefore pregnancy maintenance. Transcriptome of the human placenta is 
modulated by genetic variation of which single nucleotide variants (SNVs) have 
been investigated the most.  
DNA copy number variations (CNVs) are defined as genomic segments of 
>50 bp present at a variable copy number in comparison to a reference genome. 
CNVs are estimated to contribute to 10% of the human genome and have been 
implicated in various human diseases. CNVs may affect the expression of genes 
critical for (early) pregnancy maintenance by direct (deletion or duplication of 
entire genes) or indirect (rearrangement of regulatory elements) ways. Studies 
of CNVs are lacking in reproductive disorders; however, the few published 
reports have indicated that genomic rearrangements may play a role in preg-
nancy complications. Understanding the architecture of placental and parental 
genomes of complicated as well as normal gestations may reveal biomarkers 
that will help to predict pregnancy outcome. 
In the current thesis, the literature review gives an up to date overview of the 
placental development and function, early (RPL) and late pregnancy compli-
cations of the mother (PE, GDM) and the newborn (growth abnormalities). A 
major part of the overview focuses on CNVs and their role in pregnancy 
complications. 
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The experimental part of this doctoral thesis explores the role of CNVs in the 
parental and placental genomes during normal pregnancies and gestational 
complications. First, a genome-wide analysis of CNVs was performed in 
couples with unexplained recurrent pregnancy loss and fertile controls to iden-
tify common rearrangements conferring risk for RPL. Second, a genome-wide 
profile of subchromosomal rearrangements was studied for the first time in the 
human placental genome. Third, based on the results of the previous study, an 
analysis of trio (mother-father-placenta) and duo (mother-placenta) CNV pro-
files of patients with idiopathic RPL was conducted. The role of CNVs in the 
placental genome in particular and in the etiology and clinical management of 
pregnancy complications is discussed in the light of the outcomes of this thesis.  
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1. REVIEW OF LITERATURE 
1.1 Biology of pregnancy maintenance 
The biological processes leading to pregnancy establishment, maintenance, and 
ultimately to birth are extremely complex and dependent on the well-coordi-
nated crosstalk between the mother and the semi-allogenic embryo. The estab-
lishment of pregnancy requires maternal recognition of pregnancy and implan-
tation. The success of each stage (apposition, adhesion, and invasion) is vital in 
order to reach the next step. Once fertilization has taken place, the presence of 
an embryo does not guarantee a healthy fetus and a live offspring. Human 
female meiosis is full of segregation errors; young women (<30 years) produce 
3–61% oocytes with an incorrect number of chromosomes (Webster and Schuh, 
2017). If fertilized, these oocytes result in aneuploid embryos that mostly fail to 
develop into functional blastocysts. Pregnancy loss has been recognized in all 
mammals; however, human reproduction is particularly inefficient with only 
~30% of all fertilized oocytes resulting in a live birth (Figure 1) (Macklon et 
al., 2002).  
The maintenance of pregnancy relies on the interactions between the con-
ceptus and the maternal endometrium to establish immune tolerance, regulate 
trophoblast invasion, and remodel the uterine spiral arteries.  
 
Figure 1. The iceberg of pregnancy loss. Roughly 70% of all spontaneous conceptions 




1.1.1 Implantation in human 
Implantation is one of the most critical stages of pregnancy establishment, 
depending not only on the quality of the embryo, but also on the receptivity of 
the endometrium as well as the communication between the two.  
Implantation involves the apposition, adhesion, and invasion of the blasto-
cyst into the uterus (Cross et al., 1994; McGowen et al., 2014). The uterus has 
to undergo enormous structural and molecular changes named ‘decidualization’ 
to become receptive during the mid-secretory phase (days 19–23) of the 
menstrual cycle, known as the ‘window of implantation’ (Lessey 2011). The 
blastocyst has to break through the epithelial lining of the uterus and damage 
the endometrial tissue to invade (Figure 2). Next, trophoblast cells need to re-
model maternal spiral arteries in order to secure a sufficient placental-fetal 
blood supply. All these events produce a battlefield of invading, dying, and 
repairing cells. An inflammatory reaction is vital for implantation in order to 
provide the repair of the uterine epithelium and the removal of cellular debris. 
After implantation, the endometrium switches to an anti-inflammatory stage, 









Figure 2. Implantation of blastocyst in the maternal endometrium. Embryo enters the 
uterus as a blastocyst ~5 days after fertilization, when the uterus is in the secretory 
phase. Implantation begins with receptors on cells of the outer embryonic trophoblast 
binding glycoprotein ligands on the endometrial epithelium. The syncytiotrophoblast 
invades the maternal endometrium to create a cavity into which the blastocyst can 
embed (modified from Giakoumelou et al., 2016). 
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The trophectoderm differentiates into two separate trophoblast cell types imme-
diately prior to invasion into the decidua, while the differentiation of the inner 
cell mass, giving rise to the embryo proper, does not begin until the first pla-
cental structure is formed (Cross et al., 1994; Fitzgerald et al., 2008). The syn-
cytiotrophoblast (non-mitotic mass of multinucleated cytoplasm) invades the 
maternal endometrium to create a cavity into which the blastocyst can embed 
(Baines and Renaud, 2017). Next, cytotrophoblasts (a layer of mitotically active 
trophoblast stem cells) provide a supply of invasive trophoblasts (extravillous 
cytotrophoblasts), while the syncytiotrophoblast acquires a more endocrino-
logical task. Trophoblast cells drive the stages of implantation, modulating the 
maternal endocrine system to establish the hormonal milieu that guides changes 
in the uterus crucial for pregnancy maintenance (Cross et al., 1994; Mescher, 
2013).  
Defective decidualization can lead to adverse pregnancy phenotypes in-
cluding defects in placentation, spontaneous abortion, intrauterine growth re-
striction, preterm birth and fetal death (Cha et al., 2012; Garrido-Gomez et al., 
2017). For example, one of the causes of preeclampsia is considered to be shal-
low implantation due to poor trophoblast invasion into the decidua (Roberts and 
Gammill, 2005). On the other hand, if the placenta invades too deep it may 
cause placenta accreta (deep attachment to the uterine wall) or choriocarcinoma. 
All of these unfavorable outcomes of pregnancy compromise the lifelong health 
of the offspring as well as the mother. 
 
 
1.2 Placenta as a key organ for pregnancy success 
1.2.1 Placental development and function  
at the fetal maternal interface 
Placental development is precocious, as it has to be ready and perform the role 
of all the major organs while these develop and mature in the fetus. Tropho-
blasts secrete over 100 peptide and steroid hormones that control the physiology 
of the mother, so that the fetus is supplied with oxygen and necessary nutrients 
needed for successful growth (Burton and Jauniaux, 2015). In addition, the pla-
centa protects the fetus from maternal immunologic attack and removes waste 
products. 
Trophoblasts, forming the external layer of the blastocyst, are the first cell 
lineage of the human placenta. Following successful implantation and initiation 
of placentation, undifferentiated cytotrophoblasts undergo extensive pro-
liferation and differentiate through fusion (villous) or invasive (extravillous) 
lineage. The fusion lineage yields syncytiotrophoblast cells that form the outer 
epithelial layer of the chorionic villi, where the majority of the maternal-fetal 
exchange takes place (Gude et al., 2004). The invasive lineage gives rise to 
interstitial cytotrophoblasts. The cytotrophoblast stem cell first differentiates 
into extravillous cytotrophoblast intermediate and then into an interstitial cyto-
trophoblast, which in turn may differentiate further into endovascular cyto-
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trophoblast or form a syncytium. Endovascular and interstitial cytotrophoblasts 
possess migratory and invasive properties, being able to recognize and modify 
the activity of other cell types at the feto-maternal interface (Silva and 
Serakides, 2016). The purpose of these cells is to invade and replace vascular 
endothelial cells in order to remodel uterine arteries to maximize blood flow 
and fulfil fetal oxygen and nutrient demands (Figure 3).  
Fetal development and growth during the first trimester of pregnancy takes 
place in a physiologically low oxygen microenvironment that is stimulated by 
secretions from the endometrial glands that supply nutrients and growth factors 
(histiotrophic nutrition). By the end of the first trimester, onset of the maternal 
arterial circulation produces a three-fold rise in the intra-placental oxygen con-
centration (Burton et al., 2010). The maternal blood circulates in the intervillous 
space and bathes the villi, enabling exchanges with the fetal blood, but no direct 
contact between fetal and maternal blood occurs. The final structure of the 
human placenta is discoid, which is 2–3 cm thick at its center, up to 25 cm in 
diameter, and weighs 400–500 g (Lewis et al., 2013). 
 
 
Figure 3. The human placenta and fetus. Villous trophoblasts of the human placenta 
grow as a branched structure in order to maximize exchange with maternal blood. Endo-
vascular cytotrophoblasts arise from extravillous trophoblasts that invade into the 
maternal endometrium. Endovascular cytotrophoblasts colonize maternal spiral arteries 
to maximize blood flow through the placenta (modified from Frost and Moore, 2010). 
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1.2.2 Placenta as a unique mammalian organ 
Placenta is one of the least understood organs, as it has evolved multiple times 
in different species in various shapes, structures, and even cell types while 
having the same basic role (Griffith and Wagner, 2017). Fundamentally, the 
trophoblast cells of the placenta perform two distinct tasks in all mammals – 
create a large surface area for nutrient exchange and interact with the uterus by 
producing hormones, growth factors, and cytokines that model maternal physi-
ological systems for increased blood flow and nutrient delivery to the fetus and 
the placenta (Cross et al., 2003). 
The evolution of the placenta in mice and humans has employed two unique 
evolutionary mechanisms. Ancient genes participating in growth and metabolic 
processes were co-opted for use in the course of early embryonic development, 
while recently duplicated genes are used during later stages of fetal develop-
ment, taking on a specialized species specific placental function (Knox and 
Baker, 2008). For example, the mouse placenta is enriched for expression of 
rodent-specific genes, e.g. prolactin-related proteins (23 members), pregnancy-
specific glycoproteins (17 genes), and carcinoembryonic antigen (CEA) family 
of glycoproteins (31 genes), whereas the human placenta is enriched for expres-
sion of primate-specific genes, e.g. CEA genes and pseudogenes (23 members), 
growth hormones (5 members), pregnancy-specific glycoproteins (10 genes), 
and gonadotropic glycoproteins (LHB/CGB cluster, 7 homologous genes) 
(Hallast and Laan, 2009; Carter, 2012; Roberts et al., 2016). These genes have 
enabled deep invasion of the endometrium and direct contact of the maternal 
blood with the trophoblast surface (hemochorial placentation) characteristic 
only for primates and rodents. 
 
 
1.2.3 Mosaicism in the human placenta  
Mosaicism, the existence of two or more distinct cell lines, is very common 
during the cleavage stage in human preimplantation development, occurring in 
~15–90% of embryos (Taylor et al., 2014). It is also prevalent at the blastocyst 
stage; however, research has shown that 1–2% of viable pregnancies present 
with a chromosomally abnormal placenta but a normal fetus (Ledbetter et al., 
1992; Grati et al., 2017). This suggests a selection mechanism against mosai-
cism in later stages of development. The fetus is derived from only a small sub-
set (3 out of 64) of the blastocyst progenitor cells, the rest of the cells give rise 
to extraembryonic membranes (Bianchi et al., 1993). In addition, studies have 
shown that euploid cells proliferate at a higher rate than abnormal cells, which 
can be repelled from the fetal lineage (Taylor et al., 2014). 
Nevertheless, chromosomal mosaicism is a challenging factor in prenatal 
diagnosis due to the complex prediction of fetal involvement. The clinical out-
comes of mosaicism depend on several factors, including when exactly the error 
arises during development and whether it is confined to a particular area. Pla-
cental mosaicism occurs in normal pregnancies, but has been associated also 
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with adverse pregnancy outcomes including preeclampsia, intrauterine growth 
restriction, stillbirth, and recurrent pregnancy loss (Kalousek and Barrett, 1994; 
Yong et al., 2006; Warren and Silver, 2008; Robinson et al., 2010). 
 
 
1.3 Recurrent pregnancy loss 
Recurrent pregnancy loss (RPL) is defined as ≥2 consecutive losses before 24 
weeks’ gestation according to the latest European guideline (ESHRE, 2017). 
The definition used to be ≥3 consecutive losses, but the new guideline suggests 
that defining RPL as two or more pregnancy losses will facilitate research and 
psychological support to couples. The American Society for Reproductive 
Medicine already updated the definition to two or more consecutive pregnancy 
losses six years ago (ASRM, 2012). 
Up to 15% of all clinically recognized pregnancies result in spontaneous 
abortion. Due to chance alone, RPL would occur in 0.34% of couples with three 
losses, whereas it is seen in 1–2% of couples trying to conceive (Bashiri et al., 
2016). This discrepancy suggests a specific clinical cause for RPL. 
What makes it extremely stressful for the couple is the fact that each sub-
sequent pregnancy loss leads to higher risk of experiencing further losses, as the 
live birth rate in patients with three pregnancy losses is 70% vs. 50% in couples 
with 5–6 losses (Sugiura-Ogasawara et al., 2014). Maternal age is one of the 
most important factors determining prognosis for live birth, whereas the number 
of pregnancy losses often increases due to the fact that the following pregnan-
cies occur at an advanced maternal age (Nybo Andersen et al., 2000; Sauer, 
2015). 
 
1.3.1 Known causes of RPL 
Although a wide range of factors are known to increase the risk of RPL, in-
cluding anatomic and endocrine factors, immune system dysfunction and chro-
mosomal abnormalities, it is often difficult to determine a definite cause of this 
condition. Until today, the underlying cause remains undiagnosed in nearly 50% 
of cases based on the current clinical guidelines (Ford and Schust, 2009; Bashiri 
et al., 2016; Popescu et al., 2018).  
Unlike spontaneous abortions that are mostly caused by chromosomal ab-
normalities, negative correlation has been detected between the occurrence of 
aneuploidies and the number of pregnancy losses (Ogasawara et al., 2000). 
However, abnormal embryonic karyotype was shown in 41% of cases with un-
known cause of pregnancy loss in a recent study and it was suggested that the 
percentage of patients with RPL of truly unknown cause may actually not ex-
ceed 24.5% (Figure 4) (Sugiura-Ogasawara et al., 2012). Microarray testing of 
miscarriage tissue is currently not recommended by the American and European 
RPL guidelines, though a very recent prospective cohort study has shown that 
>90% of patients with RPL will have a cause identified when genetic testing on 
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pregnancy loss tissue is combined with standard evaluation (Popescu et al., 
2018). 
Antiphospholipid antibody syndrome (APS) and uterine anomalies are es-
tablished non-genetic causes of RPL (Bashiri et al., 2016). Presence of anti-
phospholipid antibodies (aPL) has been associated with RPL for a long time. 
The prevalence of APS is expected to be 5–20% (El Hachem et al., 2017). aPL 
induce thrombosis, inhibit differentiation and invasion of the trophoblast, and 
may cause inflammation and immune response at the fetal-maternal interface as 
well as disrupt spiral artery remodeling (Di Simone et al., 2001; Bashiri et al., 
2016). Errors in the endocrine system and anatomical abnormalities affect 10–
20% of women with RPL. Occurrence of congenital as well as acquired uterine 
anomalies in RPL cases is about threefold higher compared to the general 
population (ASRM, 2012). 
 
Figure 4. The etiology of recurrent pregnancy loss. Known parental causative factors 
for RPL include gross chromosomal rearrangements (aneuploidy, microdeletions/ dupli-
cations, translocations, extensive CNV load etc), infections and immunological factors 
in either of the partners, maternal endocrine disturbances and anatomical defects. An 
RPL couple is often diagnosed with multiple potential parental contributing factors and 
the sole causal factor cannot be assigned. Several parental risk factors may also pre-
dispose to the chromosomal disturbances of the POC. Of all RPL cases, approximately 
25% remain truly unexplained (modified from Ref. IV). 
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It is not clear yet to what extent thrombophilia, infections and immune dys-
function as well as environmental factors and lifestyle contribute to RPL. The 
prevalence of risk factors among RPL couples varies to a great extent due to 
diagnostic criteria used in different clinics. In clinical practice, a typical RPL 
couple is diagnosed with various potential contributing factors simultaneously 
and the single causal factor cannot be identified. Popescu et al., 2018 reported 
14% of women with two or more abnormal factors ascertained. Eventually, 
every etiology has its own prognosis and depends on whether it is treated or not. 
 
 
1.3.2 Genetic factors causing RPL (also reviewed in Ref. IV) 
The prevalence of RPL among first degree relatives of women with idiopathic 
RPL is sixfold higher than in controls, which points to the involvement of ge-
netic factors (Christiansen et al., 1990). Kolte et al., 2011 have additionally 
shown a nearly twofold higher miscarriage rate among the siblings of patients 
with unexplained RPL compared to the general population. 
Chromosomal abnormalities (mostly balanced translocations) account for 2–
4% in either partner of an RPL couple (Ford and Schust, 2009). Although over 
two-thirds of the products of these couples’ conceptions have abnormal karyo-
type (unbalanced translocations), the cumulative live birth rate exceeds 60% 
(Franssen et al., 2006). Preimplantation genetic diagnosis (PGD) may help to 
decrease time to live birth in a fraction of these RPL couples.  
Hundreds of hypothesis based candidate gene studies regarding RPL have 
been carried out to pinpoint causative genes. Already more than 100 genes and 
nearly 500 variants have been reported in the scientific literature (Pereza et al., 
2017; Rull et al., 2012; Shi et al., 2017). Most of the genes analyzed are in-
volved in immune dysfunction and inflammation (e.g. HLA, IFNG, TNF, and IL 
genes), blood coagulation (e.g. MTHFR, FII, FV), placental development, and 
function (e.g. NOS3, TP53, VEGFA). However, none of the studied single 
nucleotide variants (SNV) have displayed sufficient diagnostic and prognostic 
value in the clinical management of couples with RPL. In addition, the recent 
RPL guideline does not suggest to screen for hereditary thrombophilia unless in 
women with additional risk factors for thrombophilia (ESHRE, 2017). Taking 
into account the multifactorial background of RPL, it can be assumed that no 
single gene/variant can be responsible for this condition.  
The key to success in association studies is proper design. Most of the re-
search has been done in women only, whereas embryonic development is a 
delicate and precise interplay between the maternal and fetal/placental genome 
as well as the paternal genetic component. Genetic variants have been investi-
gated in male partners of RPL women in only about 12% of all studies (Pereza 
et al., 2017). In addition, there are differences in the definition of RPL and se-
lection criteria for patients/controls between studies that may often produce 
controversial results (Rull et al., 2012). 
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1.4 Late pregnancy complications 
Pregnancy is a stress test for the woman’s body that may reveal a number of 
disorders that can lead to acute as well as chronic physiological consequences. 
Also, fetal development may be disturbed and, in case the neonate survives, the 
child may have an increased risk of different diseases throughout life. Late 
pregnancy complications can thus be divided into gestational complications of 





Preeclampsia (PE) is a uniquely human pregnancy-specific condition of pla-
cental origin affecting 2% of pregnancies in Estonia (according to Estonian 
Medical Birth Registry data in 2016) and 2–8% worldwide (Jeyabalan, 2013). It 
is traditionally diagnosed by maternal blood pressure greater than 140/90 
mmHg and proteinuria in the second half of pregnancy (after 20 weeks’ gesta-
tion) (Brown et al., 2001). All guidelines include gestational hypertension as 
part of the definition of PE; however, three out of eight national guidelines do 
not include proteinuria as a mandatory requirement in the definition of PE any-
more (Bro Schmidt et al., 2017). Many factors have been associated with the 
risk to preeclampsia: chronic hypertension, renal diseases, obesity and insulin 
resistance, diabetes mellitus, pre-existing thrombophilia, family history of 
preeclampsia and smoking (Mol et al., 2016). 
The only effective treatment of preeclampsia is delivery of the fetus and pla-
centa which often leads to preterm and low birth weight babies. The initiation of 
early onset preeclampsia (<34 weeks) is associated with inappropriate vascular 
remodeling of the uterine spiral arteries due to shallow cytotrophoblast migra-
tion, which takes place during very early stages of pregnancy (Figure 5) 
(Roberts and Gammill, 2005), and has worse perinatal and maternal outcomes 
(Myatt and Roberts, 2015). While early onset PE is often complicated by 
intrauterine growth restriction and placental pathology, late onset PE is as-
sociated with predisposing maternal factors rather than placental origin 
(Steegers et al., 2010).  
Despite the known risk factors and amount of research in this field, the 
etiology of preeclampsia is still poorly understood. Similar to RPL, daughters 
and sisters of preeclamptic women have a higher risk for developing hyper-
tension during pregnancy. Although, heritability of preeclampsia has been esti-
mated to be 30–55% (Boyd et al., 2013; Williams and Broughton Pipkin, 2011), 
knowledge about the exact genetic architecture is still limited. Genome-wide 
association studies (GWAS) have not found any maternal sequence variants of 
genome-wide significance replicated in independent samples (Johnson et al., 
2012; Zhao et al., 2013a). However, a recent GWAS of offspring from PE preg-
nancies discovered the first genome-wide significant susceptibility locus near 
FLT1 gene in 4,380 cases and >300,000 controls (McGinnis et al., 2017). The 
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strongest association was found in late-onset preeclampsia (LO-PE), whereas 
placental isoform of this protein (sFlt-1) is an established marker of early-onset 
PE (Staff et al., 2013). Various studies of placental RNA expression have also 
been conducted to find novel genes and possible biomarkers for PE (Brew et al., 
2016; Kaartokallio et al., 2015; Tsang et al., 2017). The RNA-sequencing study 
on 40 human placentas from our group found that the transcriptome profile of 
late-onset PE placentas is distinct from normal pregnancies and other gesta-
tional complications, supporting the placental origin of this complex disease 
(Sõber et al., 2015).  
 
 
Figure 5. Normal and abnormal placentation (preeclampsia). The placenta is linked to 
the maternal decidua by anchoring villi. In normal placentation, cytotrophoblasts (blue) 
invade the maternal decidua and adjacent spiral arteries. They penetrate the walls of the 
arteries and replace part of the maternal endothelium (yellow). During normal preg-
nancy, immune cells facilitate deep invasion and promote extensive spiral artery re-
modeling. In the preclinical stage of preeclampsia, invasion is restricted with impaired 
arterial remodeling and lowered blood supply to the fetus (modified from Redman and 
Sargent, 2005).  
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1.4.2 Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) is the onset of glucose intolerance during 
pregnancy. It is a result of reduced maternal insulin sensitivity occurring during 
pregnancy that leads to higher amounts of blood glucose to pass through the 
placenta into the fetal circulation (Lain and Catalano, 2007). The prevalence of 
GDM in Estonia was 6.5% in 2016 (Estonian Medical Birth Registry) and 
varies from 1–16% worldwide due to numerous diagnostic criteria used in dif-
ferent countries (Kirss et al., 2015). Despite the criteria applied, GDM is in-
creasing in prevalence across the world in parallel with the growing number of 
people with obesity and type 2 diabetes (Coustan, 2013). 
GDM is diagnosed by glucose testing early in pregnancy to reveal diabetes, 
and again with a glucose tolerance test at 24–28 weeks’ gestation (IADPSG, 
2010). Major risk factors for developing GDM are a BMI >30 kg/m², a previous 
macrosomic baby (≥4.5 kg), previous gestational diabetes, a family history of 
diabetes, and a family minority ethnic origin with a high prevalence of diabetes 
(NICE Guideline, 2015). It is associated with adverse pregnancy outcomes, 
including fetal macrosomia as well as intrauterine growth restriction and still-
birth (Coustan, 2013).  
Elevated delivery of maternal glucose may release signal molecules, e.g. 
elevated leptin levels, from the fetus and initiate methylation changes in the 
placenta (Moen et al., 2017). Several studies have suggested transgenerational 
transmission of gestational diabetes as well as other cardio-metabolic diseases 
later in life is due to epigenetic mechanisms, explaining the enormous increase 
in the prevalence of type 2 diabetes worldwide (Claesson et al., 2007; Vrachnis 
et al., 2012). As an example of fetal genotype impact on maternal metabolism, 
variation in paternal allele of the imprinted gene IGF2 has been associated with 
increased IGF2 protein content in the placenta and maternal glucose levels 
(Petry et al., 2011). Several genetic association studies have been based on the 
assumption that the genetic architecture of GDM and type 2 diabetes is similar, 
but not many significant associations have been detected for GDM, mostly due 
to lack of power (Lowe et al., 2016). Future studies of larger sample sets are 
needed. 
 
1.4.3 Fetal growth abnormalities 
Normal fetal growth is a crucial component of a successful pregnancy and im-
pacts the long term health of the offspring and the mother. There are two main 
types of fetal growth abnormalities: intrauterine growth restriction (IUGR) and 
macrosomia. Defined cut-offs of fetal growth below the 10th and above the 90th 
centiles or two standard deviations below/above the population norms on the 
growth charts are commonly used to define small-for-gestational age (SGA) and 
large-for-gestational age (LGA) fetuses (Anderson, 2005; Sildver et al., 2015). 
Diagnosis of fetal macrosomia is made if the fetus grows beyond a specific 
weight, usually 4.5 kg, irrespective of the gestational age (ACOG, 2000). IUGR 
24 
is defined on the basis of clinical features of malnutrition and in utero growth 
restriction, regardless of the birth weight percentile (Sharma et al., 2016).  
The prevalence of IUGR and macrosomia in developed countries is 5–10% 
and 5–20% of all births, respectively (Lenoir-Wijnkoop et al., 2015; Tang et al., 
2017). IUGR is the result of maternal, fetal, as well as placental and genetic 
factors (Sharma et al., 2016). Almost 50% of pregnancies complicated by ma-
ternal (gestational) diabetes result in LGA or macrosomic babies (Najafian and 
Cheraghi, 2012). Several risk factors for macrosomia, such as advanced mater-
nal age and obesity, are also conversely associated with fetal growth restriction 
(Walsh and McAuliffe, 2012).  
Currently, there are no methods or biomarkers to distinguish healthy SGA 
and LGA newborns from neonates who have growth disturbances as a result of 
pathological processes. It is known that imprinted genes have growth-related 
functions in mammals. Imprinted genes with enriched expression in the placenta 
(e.g. IGF2, PEG1, PHLDA2) have been shown to play a role in distributing 
maternal resources to the fetus (Tang et al., 2017). Differential placental gene 
expression in IUGR has been associated with nervous system development and 
cardiovascular system development and function, while in macrosomic infants 
the strongest association has been detected with nutritional disease, behavior, 
digestive system development, and lipid metabolism (Sabri et al., 2014). Four 
genes (LEP, GCH1, LRP2, and CPXM2) showed differential expression levels 
in both FGR and macrosomia. Higher expression of LEP was also detected in a 
recent transcriptome study of IUGR placental samples (Madeleneau et al., 
2015). The genetic background is still obscure in these late pregnancy compli-
cations, thus genetic studies are needed in the field of fetal growth extremes. 
 
 
1.5 Structural variation in the human genome 
The DNA sequence of the human genome is constantly changing, enabling us to 
evolve and adapt. The genome sequence of two individuals has been found to 
differ about 1.6% (Pang et al., 2010). Over ten years ago, due to the advance-
ment in technology, scientists started to identify an intermediate class of varia-
tion termed as structural variation (SV) (Iafrate et al., 2004; Sebat et al., 2004). 
This includes deletions, duplications, inversions, insertions, translocations, and 
complex genomic rearrangements. Every child is born with up to 9.2 de novo 
SVs (Acuna-Hidalgo et al., 2016). Structural variation has a larger impact on 
the function of the genome than single nucleotide variants (SNVs). It has been 
reported that while 14.6% of de novo SVs affect exons, only ∼1.3% of de novo 
SNVs do (Kloosterman et al., 2015). However, the effect depends on the size, 
location, penetrance, and origin of the rearrangement, as well as number of dis-
rupted genes critical to a certain phenotype. 
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1.5.1 DNA copy number variation  
DNA copy number variation (CNV), involving submicroscopic deletions and 
duplications, accounts for the largest component of structural variation (Figure 
6). CNVs are now defined as genomic segments of >50 bp present at a variable 
copy number in comparison to a reference genome.  
 
Figure 6. Different types of copy number variation (CNV). Relative duplication and 
deletion of the ‘2’ locus compared with the reference genome is illustrated. Complex 
rearrangement of ‘2’ and ‘3’ loci is also shown. 
A recently constructed CNV map estimated that 4.8–9.5% of the human ge-
nome contributes to CNV (Zarrei et al., 2015). The exons of all genes were re-
ported to be more variable than the genome average, with exons of non-coding 
genes having the highest number of CNVs. However, exons of constrained 
genes, especially cancer-related and DECIPHER genes, were under strong 
negative selection. Deletions encompassing genes have been shown to be 
significantly rarer than intergenic deletions, whereas genic duplications show no 
such skew (Sudmant et al., 2015). In addition, deletions have been found to 
decrease in frequency as a function of size, suggesting that during human evo-
lution selection has formed deletions and duplications in a different way 
(Sudmant et al., 2015; Zarrei et al., 2015).  
CNVs can have no apparent phenotypic consequence in individuals or result 
in adaptive advantages. For example, the copy number of human salivary 
amylase gene is increased in populations that have higher starch content in their 
diets (Perry et al., 2007). A major challenge in clinical practice as well as scien-
tific research is to differentiate benign CNVs from pathogenic CNVs contri-
buting to diseases. Pathogenic rearrangements are associated with altered gene 
dosage and have been linked with numerous disorders, including developmental 
diseases (Lee and Scherer, 2010), autism (Pinto et al., 2010), schizophrenia 
(The International Schizophrenia Consortium, 2008; Sekar et al., 2016), 
diabetes (WTCC et al., 2010), autoimmune disorders (Olsson and Holmdahl, 
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2012), and cancer (Krepischi et al., 2012; Zhang et al., 2016). However, the 
consequence of a large number of rearrangements still remains unknown. 
Besides existing in the germline, CNVs can arise de novo in certain cells and 
tissues, referred to as somatic genome rearrangements. For example, mamma-
lian liver is a mixture of cells with gains and losses, helping it to adapt to meta-
bolic and toxic challenges (Tang and Amon, 2013). Rather than being randomly 
present in the genome, CNVs are preferentially found in regions that are rich in 
low-copy repeats (segmental duplications), heterochromatic areas, and replica-
tion origins (Zarrei et al., 2015). They can arise by various mechanisms, in-
cluding non-allelic homologous recombination, non-homologous end joining, or 
defects in DNA replication and repair (Hastings et al., 2009).  
 
 
1.5.2 CNV detection methods 
There are two approaches to detect CNVs: genome-wide and locus-specific. 
Each detection method has its strengths and shortcomings, and is typically used 
in certain applications. Comparison of different detection methods is given in 
Table 1.  
Microarray is the main approach used to detect CNVs at the genome-wide 
scale. This is represented by aCGH (array comparative genomic hybridization) 
and SNP microarrays. aCGH uses two dyes to compare the DNA copy number 
between a target sample and a reference sample that are hybridized together on 
the same array (Pinkel et al., 1998). The signal intensity ratio (log ratio) is used 
as a proxy for copy number. On the other hand, SNP arrays hybridize only one 
sample to each array and compare the data in silico to a reference dataset. The 
ratio between the total signal and the reference signal produces copy number 
information similar to the intensity ratio from aCGH. The ratio between the two 
allele intensities yields a value for the genotype of the SNPs (Figure 7) (Alkan 
et al., 2011; Vandeweyer and Kooy, 2013). Next generation sequencing (NGS) 
has several advantages over microarrays by detecting very small rearrangements 
and defining exact breakpoints. However, despite the high resolution of new 
array-based and NGS methods, karyotyping still remains the primary method to 
detect balanced chromosomal rearrangements (translocations, inversions) 
(Vandeweyer and Kooy, 2013).  
Locus-specific methods are commonly used to confirm CNVs that were de-
tected by genome-wide methods. The simplest and most used method is quan-
titative real-time PCR (qPCR) that measures products generated during each 
PCR cycle, which are proportional to the amount of original template at the start 
of the PCR. Two basic chemistries are mostly used: hydrolysis probes 
(TaqMan®) and double-stranded DNA-intercalating dye SYBR® Green (Arya et 
al., 2005). Irrespective of the chemistry used, the increase in fluorescence emis-
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 7. Examples of log R ratio (LRR) (lower panel) and B Allele Frequency (BAF) 
values (upper panel). Negative LRR (total probe intensity of a given SNP) indicates a 
region of DNA copy number loss (CN=1) and positive LRR shows a region of DNA 
copy number gain (CN=3). BAF is a normalized measure of the allelic intensity ratio of 
two alleles. A BAF of 0 represents the genotype (A/A or A/–), 0.5 represents (A/B) and 
1 represents (B/B or B/–). The BAF also enables the detection of copy-neutral events, 
which result when a segment of one chromosome is replaced by the other allele without 
a change in copy number (LRR=0, BAF shows loss of heterozygotes). 
 
At the moment there is no universal method to detect all structural variation in 
the human genome, as the detection depends largely on the platforms and also 
the various algorithms used, therefore multiple approaches are typically applied. 
Although, third generation sequencing technologies (e.g. PacBio single mole-
cule sequencing) and novel algorithms have already been developed that may 
enable stand-alone assessment of CNVs (Kerkhof et al., 2017; Zhao et al., 
2013b). 
 
1.5.3 CNVs in pregnancy complications 
The literature regarding the genome-wide profile of submicroscopic structural 
rearrangements in early as well as late pregnancy complications is limited. Only 
a few studies have been carried out in the past decade (Table 2). 
Regarding the CNV profile of miscarried conceptuses from RPL cases, two 
low-resolution aCGH studies have been published. Rajcan-Separovic et al., 
2010 identified 11 unique inherited rearrangements in the placental samples of 
RPL couples and highlighted two maternally imprinted genes (CTNNA3 and 
TIMP2) disrupted by CNVs. A follow-up study showed that the duplication 
involving the TIMP2 gene directly reduces its placental expression levels (Wen 
et al., 2015). A recent genomic analysis of 44 RPL patients (16 couples and 12 
29 
mothers) reported a positive correlation between the number of CNVs and in-
creasing number of miscarriages (Karim et al., 2017). 
A genome-wide study of structural rearrangements in a group of children 
born small-for-gestational age (SGA, n=51) identified 18 rare CNVs, out of 
which 8 were classified as pathogenic or probably pathogenic (Canton et al., 
2014). These were all de novo, gene rich and of significant size, involving genes 
that function in cell growth, developmental process and cell cycle pathways. A 
parallel study by Wit et al., 2014 discovered 6 pathogenic or potentially patho-
genic CNVs in 49 cases born SGA. A 2.5 Mb 22q11.2 deletion, known to be 
associated with short stature, was detected in both of these studies. 
Concerning preeclampsia (PE), two genome-wide association studies have 
been published by one group (Zhao et al., 2013a; Zhao et al., 2012). In the first 
study, three rare recurrent CNVs, including a functionally relevant deletion in 
the PSG11 gene, were discovered in 169 PE cases. Unfortunately, these dele-
tions were not detected in the following study. Several candidate CNV regions 
were identified in three ethnic groups in the next study, but none overlapped 
among them. However, one candidate CNV (12p11.21) in European mothers 
and two (5p13.3 and 7q11.23) in Hispanic mothers were detected in their pre-
vious CNV study samples. 
The first genome-wide study in placental samples of unexplained stillbirth 
(n=29) discovered 24 novel CNVs, out of which 8 were also confirmed in fetal 
samples (Harris et al., 2011). A 2.9 Mb heterozygous deletion on chromosome 
9, resulting in the loss of 25 genes, was suggested as causative in one stillbirth. 
Another study that used FFPE (formalin-fixed paraffin-embedded) umbilical 
cord samples of stillborn and control placentas did not find stillbirth to be as-
sociated with the presence of CNVs (Ernst et al., 2015). Nevertheless, chronic 
placental inflammation was linked with the carrier status of case-specific CNVs 
(Ernst et al., 2015).  
In conclusion, most of the studies have individually discovered causative or 
(potentially) pathogenic CNVs in early and late pregnancy complications, but 
not much overlap has been detected. This may be attributable to heterogeneity 
of the phenotypes, but also to geographic differences between the study 
samples, variable microarray probe coverage, different algorithms used, and 
absence of an appropriate control group. The detected CNVs are mostly rare 
events, large in size and heterozygous. Common recurrent (homozygous) re-

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2. AIMS OF THE STUDY 
The general aim of the present thesis was to elucidate the role of DNA copy 
number variants (CNVs) in human placental and parental genomes of normal 
gestations, early and late pregnancy complications. The specific aims of my 
thesis were: 
I. to address the role of parental CNVs in predisposing to recurrent preg-
nancy loss (RPL) and to identify new loci and functional pathways im-
plicated in early pregnancy maintenance; 
II. to compare the CNV profiles of placental samples to respective parental 
genomes across normal gestation and cases of complicated pregnancies 
at term; 
III. to compare the profile of submicroscopic genomic rearrangements in 




3. RESULTS AND DISCUSSION 
3.1 DNA copy number variation in recurrent pregnancy 
loss parental genomes (Ref. I, III) 
At the beginning of this project, only one study had been published that investi-
gated the role of copy number variants (CNVs) in miscarriage samples of 
couples with recurrent pregnancy loss (RPL). Thus, these are the first high 
resolution genome-wide studies of CNVs in RPL parental genomes.  
 
 
3.1.1 Study design 
Ref. I is a case-control study that included altogether 558 idiopathic RPL pa-
tients with ≥3 consecutive pregnancy losses from Estonia (80 female and 39 
male partners, recruited by K. Rull at the Women’s Clinic of Tartu University 
Hospital) and Denmark (229 female and 210 male; recruited by O. B. Christian-
sen at the Fertility Clinics, Rigshospitalet, Copenhagen University Hospital). 
For all the recruited cases known clinical risk factors had been excluded. The 
control group consisted of 205 fertile women (90 from Estonia and 115 from 
Denmark) with ≥3 live births and no history of miscarriages before recruitment. 
In the discovery phase, a subset of Estonian cases (n=43) and controls (n=27) 
were genotyped with Illumina Human370CNV-Quad array (>370,000 markers). 
CNV calling was performed in parallel with two algorithms, QuantiSNP and 
PennCNV (Colella et al., 2007; Wang et al., 2007). TaqMan qPCR was used for 
experimental validation of prioritized CNVRs and replication using the ex-
tended Estonian and Danish sample sets (Figure 8; Figure 1 in Ref. I).  
 
 
Figure 8. Study design. Initial CNV discovery was performed in a subsample of Esto-
nian subjects. Association testing of three CNVRs and replication study of one region 
was conducted in extended Estonian and Danish sample sets.  
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Ref. III is an RPL family-based study (mother-father-placenta trios or mother-
placenta duos) that included 25 patients with idiopathic RPL (9 couples and 7 
female patients) and 13 placental samples (including 10 pregnancy losses and 3 
live births). Control datasets representing normal 1st trimester (8 females and 9 
placentas) and term pregnancies (8 mother-father-placenta trios) were derived 
from Ref. II. Study subjects were recruited by K. Rull at the Women’s Clinic of 
Tartu University Hospital. All samples were genotyped with Illumina Human-
OmniExpress Beadchips (>700,000 markers) and three algorithms [QuantiSNP 
(Colella et al., 2007), GADA (Pique-Regi et al., 2010) and CNstream (Alonso et 
al., 2010)] were applied for CNV calling. CNVs called by at least two algo-
rithms for the same individual in the same genomic region were included in the 
subsequent analysis.  
 
 
3.1.2 Increased burden of CNVs in the genomes of RPL patients 
In order to define the genome-wide profile of CNVs in a subset of Estonian 
patients with RPL (n=43) and fertile controls (n=27), genome-wide SNP arrays 
were applied (Ref. I). The discovery patient group included 16 male and 27 
female idiopathic RPL patients. A total of 423 non-overlapping CNV regions 
(CNVRs) were detected in RPL patients and controls (Suppl. Table S3 in Ref. 
I). RPL cases carried an average of 13.3 CNVs per individual compared to 12.6 
in controls.  
As RPL is known for its multifactorial etiology (Ref. IV), a case-by-case 
CNV profile analysis was applied to assess the individual-specific risk. This 
revealed two outlier cases with more than fivefold increased cumulative span of 
CNVs (6.1 Mb and 5.4 Mb vs. median of 1.0 Mb in the rest of RPL cases and 
1.2 Mb in controls) (Figure 9A). In addition, a load of large (≥100 kb) deletions 
involving numerous genes was detected in RPL patients compared to fertile 
women (Fisher’s exact test, OR=1.60, P=0.0266) with four patients having 
heterozygous loss of over 70 genes (Figure 9B). The average number of large 
deletions per individual was 2.2 for the RPL cases, compared to 1.4 for the 
fertile controls, and the mean number of disrupted genes in these CNV regions 
was 18.2 and 6.2, respectively. The genes disrupted by CNVs in the outlier 
cases are involved in immune function (IGH gene cluster at 14q32.33), male 
reproductive function (SOHLH1, TMEM203) and some have previously been 
associated with RPL (C4A, C4B, IGF2). Functional pathway analysis of genes 
affected by CNVs in all RPL cases (excluding the two outlier cases with high 
CNV burden) and fertile controls revealed enrichment of immune signaling 




Figure 9. Genomic burden of all CNVs and the subgroup of large (≥100 kb) deletions 
in the Estonian discovery sample set. (A) Cumulative span of deletions and duplications 
per individual among the discovery phase Estonian RPL cases (n=43) and fertile 
controls (n=27). Outlier cases with increased cumulative burden of CNVs are shown in 
orange. (B) Cumulative span of large deletions and the number of disrupted genes per 
individual. Outlier cases with increased number of genes disrupted by large deletions 
are shown in orange. Female and male patients with identical number-codes represent 
couples (e.g. RPL-F45 and RPL-M45). FFC, fertile female control; RPL-F, female RPL 
patient; RPL-M, male RPL patient.  
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Our following genome-wide profiling of CNVs in 25 idiopathic RPL patients 
and 24 controls (Ref. III) also revealed a 1.3-fold higher number of >100 kb 
long CNVs per genome in RPL cases compared to controls (Table 3). However, 
higher excess of even larger rearrangements (>300 kb) was detected in RPL 
cases by comparison with the previous study. Two-thirds of these >300 kb 
CNVs were pericentromeric or subtelomeric rearrangements (Table 4 and 
Suppl. Figure S3 in Ref. III). One male patient carried a 0.5 Mb pericentromeric 
microduplication at 15q11.2, between recurrent breakpoints (BP1-BP2) for 
chromosomal rearrangements. This family showed varying reproductive history 
including numerous miscarriages, one healthy child, and one offspring with 
severe developmental delay and intellectual disability. This CNV shows 
incomplete penetrance as other phenotypically normal carriers have been identi-
fied; however, 40% of the 15q11.2 BP1-BP2 microduplication carriers suffer 
from delayed development and speech, neuro-behavioral problems, and autism 
(Burnside et al., 2011; Chaste et al., 2014). 
Table 3. Comparison of the number of large CNVs between RPL cases and controls in 




ratio Ref. I 
Case/Control 
ratio Ref. III 
All 1.06 0.97 
>100 kb 1.31 1.35 
>300 kb 1.44 2.00 
A subgroup of patients may display an increased risk of RPL attributable to 
excessive genomic burden of CNVs. Large rearrangements, especially in peri-
centromeric and subtelomeric regions, may affect correct chromosome pairing 
in mitosis and meiosis, leading to overall genomic instability which prevents 
establishment of a successful pregnancy. In addition to failed pregnancies, such 
parental genomes (‘unfavorable genomes’) may cause developmental delay or 
future health problems in their live born offspring (Khoury and Erickson, 1993). 
CNVs rearranging the repertoire of presented antigens may affect the immune 
tolerance at the fetomaternal interface, as has been also reported in a later study 
of RPL patients (Karim et al., 2017). If anything goes wrong with the immune 
response, there is a higher risk of (recurrent) pregnancy loss (Grimstad and 
Krieg, 2016; Ref. IV). 
 
3.1.3 Experimental validation and replication of recurrent CNVs 
In order to identify common CNVs that increase the risk to RPL, nine CNVRs 
(Table 4; Suppl. Table S4 in Ref. I) were prioritized from the genome-wide 
screening results under the following criteria: CNVR i) is present in >1 indi-
vidual, ii) is only represented in RPL cases or overrepresented in patients with 
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odds ratio (OR) ≥1.5, iii) overlaps or is located in the vicinity (up to 200 kb) of 
biologically relevant candidate genes. TaqMan qPCR method was used for vali-
dation of the microarray results in the discovery sample set (n=70). Three 
CNVRs (IGKV at 2p11.2, DKK2 at 4q25 and PDZD2:GOLPH3 at 5p13.3) that 
showed precise results with TaqMan copy number assays were tested in the full 
Estonian RPL case-control sample set (119 cases and 90 controls). SEPT14 
CNVR was not included in the next stage due to restricted testis-specific ex-
pression of this gene (The Human Protein Atlas). Five selected regions were 
validated by TaqMan qPCR as copy number variable (1p36.33, 6p21.33, 8p22, 
12p13.31, 14q32.33), but the precise copy number estimation per each patient 
was hampered due to complex genomic architecture. 
Table 4. Prioritized CNVRs subjected to experimental validation using TaqMan qPCR 
in the discovery sample set. Association testing in the full Estonian sample set was 












1p36.33  1284756, 
1334343 
49.6 Del  SCNN1D, ACAP3, 
PUSL1, CPSF3L, 
GLTPD1, TAS1R3  
4 0 




IGKV region 5 1 
4q25  107144581, 
107152053 
7.5  Del  DKK2  4 0 
5p13.3  32106978, 
32159411 
52.4 Dup  PDZD2, GOLPH3 3 0 
6p21.33  32038826, 
32039119 
0.3  Del/ 
Dup  
CYP21A2  4 1 
7p11.2  55798750, 
55838203 
39.5  Del/ 
Dup  
SEPT14  2 0 
8p22  16405000, 
16415383 
10.4  Del  Intergenic; 212 kb 
5’of MSR1  
5 2 
12p13.31  6134743, 
6138398 
3.7  Del  Intergenic; 10 kb 
5’ of VWF  
3 1 
14q32.33  105562232, 
105646379 
84.2 Del  IGHA2, IGHE, 
IGHG4, IGHG4  
3 0 
Chr, chromosome; Del, deletion; Dupl, duplication 
 
The strongest effect in the full Estonian RPL sample set was observed for 
PDZD2:GOLPH3 duplication (OR=7.28) with an increased prevalence among 
RPL patients compared to controls (7.6% vs. 1.1%, respectively) (Suppl. Table 
S7 in Ref. I) and was further selected for a replication study in Danish RPL 
cases and fertile controls (n=554). The other two CNVRs (IGKV locus, del/dupl 
and DKK2 locus, del) were not studied further as they exhibited minimal 
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differences in carrier frequencies in the full Estonian case-control sample set, 
having minor if any effect on the RPL phenotype in our study. 
The results of the replication study confirmed the higher duplication carrier 
frequency in RPL patients compared to controls (4.3% vs. 1.7%, respectively). 
Notably, comparison with fertile women revealed a stronger effect in Danish 
female patients with a similar prevalence as in Estonian cases (6.6% vs. 7.6%, 
respectively) (Table 5, Figure 10). Statistically significant association of the 
PDZD2:GOLPH3 duplication with an increased risk for maternal RPL (OR=4.82, 
P=0.012) was detected in the meta-analysis combining the results of the Estonian 
and Danish female patient-control samples (in total, 309 cases and 205 controls). 
The difference in the duplication prevalence in Danish compared to Estonian men 
could be caused by the difference in sample size (249 vs. 39 men, respectively). 
Table 5. Association analysis of the PDZD2:GOLPH3 CNV at 5p13.3 with recurrent preg-
nancy loss in Estonia and Denmark. Statistically significant association is marked in bold. 
Controls No of subjects/ 
carriers (%) 
Cases No of subjects/ 
carriers (%) 
P-value 
Full Estonian sample set 
Fertile women 90/1 (1.1) All 119/9 (7.6) 0.062  
  Men 39/3 (7.7) 0.087  
  Women 80/6 (7.5) 0.070 
Replication study: Danish RPL case-control sample 
Fertile women 115/2 (1.7) All 439/19 (4.3) 0.211 
  Men 210/4 (1.9) 0.916 
  Women 229/15 (6.6) 0.071 
Meta-analysis: Estonian and Danish RPL cases and fertile controls 
Fertile women 205/3 (1.5) All 558/27 (4.8) 0.036 
  Men 249/7 (2.8) 0.268 
  Women 309/21 (6.8) 0.012 
 
Figure 10. Copy number distribution and carrier frequency of the PDZD2:GOLPH3 
duplication at 5p13.3 among Estonian and Danish female RPL patients (n=309) com-
pared to fertile controls (n=205). CNV carriers have 3 to >4 copies per genome. 
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Supporting this finding, a genome-wide association study of maternal CNVs in 
preeclampsia (PE) was published shortly before (Zhao et al., 2013a), identifying 
a statistically significant association with a 50.4 kb PDZD2:GOLPH3 dupli-
cation and risk for PE (OR=4.80, P=0.011). The carrier frequencies of this 
duplication were similar to the current RPL case-control study (Table 5) with 
8.3% in PE patients (n=60) compared to 1.6–1.9% in controls (n=645). Pre-
eclampsia and recurrent pregnancy loss have been shown to share similar etio-
logical factors, and have been linked with disturbed early placental development 
(Germain et al., 2007; Trogstad et al., 2009). In addition, the combination of 
fetal and maternal genotypes that increases the risk of PE (Hiby et al., 2004) has 
been shown to increase the risk of RPL as well (Hiby et al., 2008). 
 
 
3.1.4 Genomic context of the PDZD2:GOLPH3 duplication and 
expression profile of the disrupted genes 
Experimental fine-scale mapping of the 5p13.3 duplication confirmed the extent 
of the CNV from the last intron of the PDZD2 to the first intron of the GOLPH3 
gene, adjusting the size to 61.6 kb (compared to 52.4 kb based on the micro-
array estimation) (Figure 11A). The flanking breakpoints of the CNV were 
characterized by various repetitive elements; however, there was no extensive 
DNA sequence similarity between the proximal and distal repeat elements 
(Suppl. Figure S7 in Ref. I). Only a microhomology of one nucleotide was 
detected at the junction of the duplication endpoints, suggesting a CNV for-
mation mechanism other than nonallelic homologous recombination (Hastings 
et al., 2009). 
Expression analysis of PDZD2 and GOLPH3 in human tissue cDNA panels 
revealed the highest expression in placenta for both genes (Figure 11B). 
GOLPH3 was expressed in all tissues with high levels also in prostate and 
ovary. On the other hand, the level of PDZD2 transcripts was very low in most 
tissues. These results highlight the importance of these genes in human pla-
cental/reproductive function.  
Interestingly, a homozygous missense variant in PDZD2 has been recently 
associated with caudal regression syndrome, which is attributed to abnormal 
early fetal development of the lower spine (Porsch et al., 2016). Amplification 
and overexpression of PDZD2 as well as GOLPH3 has been reported in diverse 
human cancers (Gamwell et al., 2013; Scott et al., 2009; Zeng et al., 2012; Tan 
et al., 2014; Xi et al., 2016). Importantly, statistically significant correlation has 
been shown between GOLPH3 expression level and copy number status (Scott 
et al., 2009). GOLPH3 activates the mammalian target of rapamycin (mTOR), 
which controls cell growth, proliferation, and survival through various signaling 
pathways (Wullschleger et al., 2006). Disturbances in mTOR signaling have 
been linked with several female as well as male reproductive disorders in mice 
and human, including RPL (Jesus et al., 2017; Roos et al., 2007; Rosario et al., 
2017; Zhang et al., 2017; Vatin et al., 2012; Wen et al., 2005; Xiang et al., 
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2015), therefore providing the potential functional link between the duplication 
of GOLPH3 and development of RPL. 
Although the PDZD2:GOLPH3 CNV does not duplicate the complete 
coding regions of these genes, the local genomic architecture is modified and 
may physically impair the access of important transcription factors. It may re-
sult in alternative transcripts and lead to changes in the expression of the in-
volved genes as well as genes located in their vicinity (Gamazon and Stranger, 
2015; Henrichsen et al., 2009). This needs to be clarified in further functional 
studies. 
 
Figure 11. (A) Schematic illustration of 5p13.3 CNV locus with or without the tandem 
duplication (coordinates according to hg38). The opposite transcription of the PDZD2 
and GOLPH3 genes is indicated with blue and pink arrows, respectively. Experimen-
tally confirmed duplication endpoints are indicated with orange arrowheads and dotted 
lines. The breakpoint junction of the tandem duplication is marked with orange arrow 
tail. (B) Gene expression profile of PDZD2 and GOLPH3 in the human cDNA tissue 
panels. Expression level is provided relative to the reference gene HPRT and as an 
average of three amplification reactions ± SEM. Gene expression levels in reproductive 
tissues are highlighted with colored bars. 
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3.1.5 Major contribution of this study to the field of RPL research 
1. This is the first high-resolution genome-wide study of CNVs in women with 
RPL and their partners. 
2. Functional enrichment analysis of genes disrupted by CNVs in RPL cases 
compared to controls confirmed the importance of immune tolerance in early 
pregnancy maintenance.  
3. Large cumulative burden of CNVs in specific individuals and excess of large 
deletions may confer risk to RPL due to the disruption of key genes essential 
in early development, but also increasing predisposition to further genomic 
rearrangements during gametogenesis and division of cells in the early 
embryo.  
4. As a major outcome, a common duplication was discovered at 5p13.3 as a 
risk factor for RPL in two North European populations, Estonia and Den-
mark. The CNV involves two genes, PDZD2 and GOLPH3, highly ex-
pressed in the placenta and associated with pregnancy loss for the first time. 
Importantly, this duplication may be a pleiotropic risk factor in the genetic 
etiology of multiple pregnancy complications.  
 
3.2 Submicroscopic genomic rearrangements in  
the placental and parental genomes of normal and 
complicated pregnancies (Ref. II) 
3.2.1 Study design 
Genome-wide analysis of autosomal submicroscopic rearrangements was con-
ducted in 38 family trios comprised of placental and parental blood DNA, 17 
placenta-mother duos and two singleton placental samples (Figure 1 and Table 
1 in Ref. II). The placental samples included all three trimesters of normal 
gestations and term cases of late pregnancy complications [preeclampsia (PE), 
gestational diabetes mellitus (GDM), small-for-gestational age (SGA), and 
large-for-gestational age newborns (LGA)]. CNV calling was performed by 
three algorithms [QuantiSNP (Colella et al., 2007), GADA (Pique-Regi et al., 
2010) and CNstream (Alonso et al., 2010)] based on the genome-wide geno-
typing dataset (Illumina HumanOmniExpress). CNVs called by at least two 
algorithms for the same individual in the same genomic region were included in 
the subsequent analysis. Functional enrichment analysis of somatic and in-





3.2.2 Extensive load of CNVs in the placental genomes 
All placental samples regardless of the trimester or complication group exhibited 
enrichment in the number of CNVs compared to the respective parental samples 
(Figure 2A and Suppl. Tables 1–4 in Ref. II). A threefold excess in the number of 
CNVs (mean no of CNVs per genome: 28.5 vs. 9.5, P<2.2 × 10–16) and nearly 
sixfold higher amount of duplications (15.3 vs. 2.7) was detected in the placental 
genomes compared to the parental blood DNA (Table 6). The greatest difference in 
the number of CNVs, especially duplications, occurs between the 1st and 2nd 
trimesters of normal pregnancy (mean no of duplications/placenta: 10.9 vs. 27.9, 
respectively; P=0.002) (Figure 12; Suppl. Table 1 in Ref. II).  
Interestingly, placental genome duplications were shorter (mean 130.8 vs. 
183.8 kb, respectively; P>0.05) and deletions longer (117.6 vs. 49.8 kb, P<2.2 × 
10–16) compared to the parental genome. The average loss/gain ratio in the pla-
cental samples was 0.9 which is a strong deviation from the expected 2–3-fold 
excess of deletions compared to duplications based on previous reports on other 
human tissues (Conrad et al., 2010; Redon et al., 2006; Ref. I).  
Table 6. Comparative profile of placental and parental CNVs.  









Number of CNVs per 
sample 
All 28.5 (23.0) 9.5 (9.0) 3.0 (2.6) 
Dupl 15.3 (12.0) 2.7 (3.0) 5.7 (4.0) 
Del 13.2 (9.0) 6.8 (7.0) 1.9 (1.3) 
Cumulative span of all 
CNVs per sample, Mb 
All 3.6 (2.4) 0.8 (0.6) 4.5 (4.0) 
Dupl 2.0 (1.4) 0.5 (0.3) 4.0 (4.7) 
Del 1.5 (0.7) 0.3 (0.3) 5.0 (2.3) 
CNV length across samples, 
kb 
All 124.7 (70.4) 87.8 (23.0) 1.4 (3.1) 
Dupl 130.8 (74.9) 183.8 (68.3) 0.7 (1.1) 
Del 117.6 (63.8) 49.8 (16.5) 2.4 (3.9) 
Ratio (loss/gain)  0.9 (0.8) 2.5 (2.3) 0.4 (0.3) 
Data are given as means (medians). All, pooled duplication and deletion CNVs. 
 
Figure 12. Gradient of increasing number of CNVs from the 1st trimester towards term 
pregnancy. P-values were calculated by Welch two-sample t-test/Wilcoxon rank sum 
test. Error bars show medians with interquartile range.  
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To confirm the excessive amount of CNVs in the placental genomes, two pla-
cental DNA samples were sent to a commercial service provider (Atlas Biolabs 
GmbH; Berlin, Germany) for external validation using an alternative array 
comparative genomic hybridization (aCGH) platform. aCGH confirmed the 
high load of genomic rearrangements in these samples and validated 56% 
(53/94) and 49% (28/57) of all CNVs identified by the SNP array (Suppl. 
Figure 2 in Ref. II). The dominant factor affecting array performance is probe 
distribution (Haraksingh et al., 2011) (in our study 715,000 vs. 400,000 
markers; 2.1 vs. 5.3 kb spacing) and implication of stringent criteria for the 
CNV calling in our study (intersection of three independent algorithms) might 
have further reduced the proportion of CNVs to be validated using aCGH. In 
addition, different from SNP-array based analysis, CNV detection by aCGH is 
based on the comparison of the investigated sample with the reference DNA. In 
order to avoid any bias and to confirm robustness, the utilized reference ge-
nomic DNA in our study was an anonymous DNA sample provided by the 
company. However, aCGH is unable to detect CNVs carried by the reference 
DNA. Also somatic mosaicism may have affected the validation rate.  
The limitation of the current study was that the investigated whole-placental 
material did not allow equivocal determination; whether the existence of so-
matic CNVs is a common feature to the entire organ or it is specific to only 
certain placental cell types. However, as the analyzed first-trimester samples 
(n=8) in this study represented purified chorionic villi containing cyto- and 
syncytiotrophoblasts, the data confirms the presence of somatic genomic re-
arrangements in these, solely placenta-specific cell types. 
 
 
3.2.3 Profile of inherited and somatic placental CNVs 
The CNV dataset for 38 family trios including term placental and maternal-
paternal blood DNA samples enabled dissection of CNVs into inherited and 
somatic (not identified in either of the parental genomes) placental genome re-
arrangements. Majority of the placental CNVs were classified as somatic 
(n=944, 88.9%) and the rest had been equally transmitted from the mother and 
the father (n=118, 11.1%; Figure 13A). The inherited CNV profile was similar 
to the parental genome rearrangements (Figure 13B); however, the somatic 
deletions were significantly longer (mean 144.6 vs. 63.9 kb; P=3.81 × 10–6) and 
duplications shorter (mean 125.0 vs. 194.1 kb; P=4.81 × 10–5) compared to the 
size distribution of inherited CNVs (Figure 13C). These results are contro-
versial to published data in other human tissues, where large duplications are 
better tolerated in the human genome than deletions (Itsara et al., 2009; Zarrei et 
al., 2015).  
The CNV profile of maternal (n=55) and paternal (n=38) DNA samples was 
similar in the mean number (9.5 and 9.3, respectively), cumulative span (both 
0.8 Mb), and mean loss/gain ratio (2.9, 2.1) of CNVs per genome (Suppl. Table 
4 in Ref. II). 
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CNV regions (CNVRs) were distributed all over the genome (Suppl. Figure 3 in 
Ref. II); however, there were differences in the fraction of somatic and inherited 
CNVRs among chromosomes (Figure 14). The highest proportion of variable 
sequence (up to 5.26%) was found in chromosomes 17 (hotspot for deletions) 
and 14 (hotspot for duplications) on the somatic CNV map and chromosomes 
11 and 19 (up to 0.91%) on the inherited CNV map. The lowest/null proportion 
was in chromosome 21 for both somatic and inherited maps, chromosome 20 
was also void of inherited structural variation. For duplications, chromosomes 
21 and 17 showed the lowest proportion of variability (0.17%) in the somatic 
map. On the inherited map of duplications, the highest proportion was found in 
chromosomes 18, 10 and 4, while chromosomes 1, 14, 16, 19–22 showed no 
variation. For deletions, chromosomes 11 and 19 showed the highest proportion 
of variable sequence (up to 0.9%) in the inherited map. Zarrei et al., 2015 also 
reported the highest proportion in chromosome 19 for losses.  
 
 
Figure 13. Distribution of placental and parental CNVs. (A) Distribution of somatic and 
inherited CNVs in the placental genome. (B) Length distribution of parental blood 
CNVs. (C) Length distribution of placental CNVs. P-values were calculated by Wilco-
xon rank sum test. Dupl, duplications; del, deletions; mat, maternal; pat, paternal.  
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Figure 14. Proportion of each chromosome that is copy number variable based on the 
somatic and inherited placental CNV maps. The horizontal dashed lines mark the 
genome average for the somatic (upper) and inherited (lower) CNVRs. The y axes 
denote the percentage of nucleotides of each chromosome that are involved in CNVRs.  
45 
Functional enrichment analysis of somatic and inherited placental CNVs was 
performed in order to find out whether the rearrangements are random or cluster 
in specific biological pathways. Among the somatic duplications, the results 
highlighted enrichment of genes involved in biologically relevant pathways for 
fetal development (Table 3 and Suppl. Table 5 in Ref. II), including ‘anterior/ 
posterior pattern specification’ (GO:0009952, 10.4% of genes rearranged in the 
pathway, P=1.34 × 10–5), ‘homophilic cell adhesion’ (GO:0007156, 12.2% of 
genes, P=3.48 × 10–5), and ‘embryonic skeletal system development’ 
(GO:0048706, 12.3% of genes, P=2.33 × 10–4). Additionally, enrichment was 
detected for genes targeted by microRNA mir-210 (34 genes, P=3.90 × 10–3), 
upregulated in preeclamptic placentas (Pineles et al., 2007; Zhu et al., 2009). 
miR-210 has been associated with hypoxia, angiogenesis, trophoblast migration, 
and invasion, as well as immune response (reviewed by Bounds et al., 2017).  
Somatic deletions were enriched for pathways related to cellular processes, 
such as ‘cell cycle process’ (GO:0022402, 5.2% of genes, P=3.49 × 10–5), 
‘microtubule-based process’ (GO:0007017, 6.4% of genes, P=1.87 × 10–3), and 
‘mitosis’ (GO:0007067, 7.1% of genes, P=3.04 × 10–3). Sher et al. have 
described reduced expression of mitotic genes in murine trophoblast giant cells 
compared to diploid control embryonic cells (Sher et al., 2013). Deletions 
disrupting genes involved in cell cycle could repress mitosis in certain cell types 
of the human placenta and promote endocycle. Endoreduplication, a cell cycle 
consisting only of synthesis and gap phases, to the ploidy level of 4–8 copies of 
DNA has been reported in extravillous trophoblasts enabling rapid growth and 
differentiation (Biron-Shental et al., 2012). 
On the other hand, the inherited placental CNVs and parental blood CNVs 
represented mostly common polymorphic loci involved in ‘olfactory receptor 
activity’, ‘amylase activity’, and ‘female pregnancy’ (Table 3 and Suppl. Table 
5 in Ref. II). 
 
 
3.2.4 Enrichment of imprinted genes in somatic duplications 
By screening the Geneimprint database (http://www.geneimprint.com) and a 
published list of imprinted loci (Court et al., 2014), I detected a significant 
enrichment of imprinted genes in somatic placental duplications (21/1,180 
duplicated genes vs. 214/57,952 Ensembl genes; P=2.67 × 10–13). The majority 
of these disrupted genes are maternally expressed and essential in placental and 
embryonic development (Table 7). As an example, CTNNA3 (duplicated in five 
placental samples) controls the proliferative versus invasive state of 
trophoblasts in the course of placentation (Tyberghein et al., 2012). Further, 
PRDM16 gene, which is a regulator of postnatal growth and maintenance of 
brown adipose tissue (Harms et al., 2014), was disrupted in two LGA placental 
samples. 
Placenta is known for its unique epigenetic profile, which is strikingly 
similar to cancer genomes (Smith et al., 2017), including the overall lower level 
of DNA methylation compared to embryonic tissues (Hamada et al., 2016). 
46 
Aberrant imprinting in the human placenta has been linked with disturbed em-
bryonic development leading to pregnancy loss, preeclampsia, intrauterine 
growth restriction, gestational diabetes, and imprinting disorders (Jacob et al., 
2013; Moen et al., 2017; Robinson and Price, 2015). However, the possible role 
of CNVs in the regulation of imprinted genes in the placenta is still unknown. I 
propose that evolution towards parent-of-origin-specific gene expression in the 
placenta may have emerged through silencing of one parental copy or by 
generating extra gene copies through somatic duplication on the other parental 
chromosome. 
Table 7. Imprinted genes disrupted by placental CNVs. Data modified from 
http://www.geneimprint.com/; * from Court et al. 2014.  





Genes disrupted by somatic duplication CNVs   
ALDH1L1 3q21.3 AS Predicted Maternal 3 SGA, GD, 
norm 
CTNNA3 10q22.2 AS Provisional Data Maternal 5 2 GD, 1 PE, 
SGA, norm 
CYP1B1 2p21 AS Predicted Paternal 3 2 PE, 1 GD 
DVL1 1p36 AS Predicted Maternal 1 LGA 
FGFRL1 4p16 Predicted Maternal 1 norm 
HOXA11 7p15-p14 AS Predicted Maternal 1 norm 
HOXA2 7p15-p14 AS Predicted Maternal 1 norm 
HOXA3 7p15-p14 AS Predicted Maternal 1 norm 
HOXA4 7p15-p14 AS Predicted Maternal 1 norm 
HOXA5 7p15-p14 AS Predicted Maternal 1 norm 
HOXC4 12q13.3 Predicted Maternal 1 norm 
HOXC9 12q13.3 Predicted Maternal 1 norm 
KCNQ1 11p15.5 Imprinted Maternal 1 norm 
KCNQ1OT1 11p15 Imprinted Paternal 1 norm 
NTM 11q25 Imprinted Maternal 1 SGA 
PEX10 1p36.32 AS Predicted Maternal 2 LGA 
PKP3 11p15 Predicted Maternal 1 norm 
PRDM16 1p36.23-p33 Predicted Paternal 2 LGA 
SLC22A3 6q26-q27 Imprinted Maternal 6 2 PE, norm,  
1 LGA, GD 
TP73 1p36.3 Imprinted Maternal 2 1 LGA, norm 
WDR27 6q27 Provisional Data* Paternal 1 SGA 
SGA, small-for-gestational age; GD, gestational diabetes; norm, normal term; PE, pre-
eclampsia; LGA, large-for-gestational age. 
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3.2.5 Reduced amount of somatic duplications in  
late pregnancy complications 
Placental genomes from normal term pregnancies carried on average 25.0 
duplications per sample, whereas placentas representing fetal or maternal 
pregnancy complications exhibited a significant reduction, having on average 
only 11.0 amplifications per genome (P=7.83 × 10–3, Figures 2, 4a in Ref. II). 
SGA group had the lowest mean number and cumulative span of CNVs (mean 
number of CNVs/span per genome: 18.3/1.5 Mb vs. 43.6/5.7 Mb in normal 
term). There was no statistical difference in the number of deletions between 
normal and complicated term pregnancies. 
Functional enrichment analysis of group specific somatic placental CNVs 
was performed to see whether there are any biological pathways enriched in 
each term pregnancy group. Placental samples from uncomplicated pregnancies 
confirmed significant enrichment of duplicated genes in biological pathways 
involved in normal embryonic development (Figure 15; Suppl. Table 5C in 
Ref. II). Enrichment of duplicated genes regulated by mir-615-5p was detected 
in the LGA group (Suppl. Table 5D in Ref. II). Supportive to our finding, a 
recent study showed downregulation of mir-615-5p in livers from offspring 
from high-calorie diet fed dams (Zheng et al., 2016). In addition, two groups 
have suggested this miRNA to be involved in the regulation of lipid and energy 
metabolism (Miyamoto et al., 2014; Siengdee et al., 2015). Maternal high-
calorie diet predisposes offspring to a larger body weight, insulin resistance, and 
impaired glucose homeostasis (Parlee and MacDougald, 2014). In our study, 
Genes in somatic duplications specific to the GDM group clustered in the 
functional category ‘low-density lipoprotein receptor activity’ (GO:0005041, 
P=2.87 × 10–2) (Figure 15; Suppl. Table 5 in Ref. II). One of the disrupted 
genes, CD36, was lately shown to be upregulated in the placentas of women 
with high pre-pregnancy BMI as well as GDM (Segura et al., 2017). The 
methylation level of the second duplicated gene in this pathway, LRP1B, has 
been demonstrated to be decreased in cord blood and in the placenta in response 
to maternal glycaemia (Houde et al., 2015). Differential expression of the genes 
involved in this functional category seems to play an important role in the 
pathogenesis of gestational diabetes. 
 
mean BMI of mothers in the LGA group was barely in the normal range (24.8) 
and mean paternal BMI was barely within the overweight range (29.9).  
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Figure 15. Functional categories displaying significant (FDR<0.05) enrichment among 
the genes underlying the placental somatic duplications and involving >5% of genes in 
the pathway (shown in log scale). GDM, gestational diabetes mellitus; LGA, large-for-
gestational age; norm, normal term.  
3.2.6 Older mothers have reduced amount of placental CNVs 
 
The number of CNVs was assessed in normal term placentas (n=8) in con-
nection with maternal factors. Although the numbers are small, some interesting 
correlations were found that are worth mentioning. I found negative correlation 
between the number of placental CNVs and maternal age at delivery (Spear-
man’s rank correlation, rho=-0.86, P=0.007) (Figure 16). Young women (<20 
years old) had around 100 CNVs per term placental genome, whereas middle-
aged women (30–40 years old) had 3–4 fold lower numbers of CNVs. The 
correlation of maternal age with the number of duplications was enhanced 
(rho=-0.87, P=0.005), whereas there was no significant effect on the number of 
deletions. A similar significant trend was observed when the number of CNVs 
was tested in correlation with the number of successful pregnancies (rho=-0.92, 
P=0.001) (Figure 16). However, as the middle-age women also tend to have 
had higher number of deliveries, the current dataset does not make it possible to 
conclude whether the reduced generation of somatic placental duplications is 
due to aging per se, or due to previously remodeled uterine tissue in ex-
perienced pregnancies that enables effective trophoblast invasion without the 
support of extensive somatic duplications of respective genes. 
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Figure 16. Correlation with maternal factors between the number of CNVs and (A) 
maternal age at birth in normal term pregnancy; (B) maternal lifetime cumulative 
number of live births (including index pregnancy). 
3.2.7 Major contribution of this study to  
the field of placental research 
1. This is the first report on genome-wide CNV profiles of human placental 
samples representing three trimesters of normal pregnancies and late 
pregnancy complications, including mother-father-placenta trios. 
2. The major finding is the load of somatic placental CNVs, especially 
duplications, in normal pregnancies that are enriched for genes involved in 
pathways relevant to embryonic development.  
3. Late gestational complications may arise during the burst of somatic genome 
rearrangements due to sporadic unfavorable rearrangements involving genes 
critical in gestational metabolism. 
4. Enrichment of imprinted genes in somatic placental duplications suggests an 
additional level of gene expression regulation that needs to be clarified in 
future studies.  
 
 
3.3 DNA copy number variation in recurrent pregnancy 
loss placental genomes (Ref. III) 
The CNV map of placental genomes from late pregnancy complications dif-
fered from normal term gestations in the number of CNVs, foremost dupli-
cations (Ref. II). Thus, I proceeded to perform a genome-wide analysis of sub-
microscopic genomic rearrangements in recurrent pregnancy loss (RPL) 
placental samples under the hypothesis that their CNV profile is even further 





3.3.1 Reduced amount of rearrangements and low fraction of  
shared CNVs in the placental samples of RPL cases compared  
to normal pregnancy 
Placental genomes of RPL cases showed >45% reduction in the mean number 
of CNVs compared to normal 1st trimester gestations (mean number of 
CNVs/genome: 10.0 vs. 18.6; Wilcoxon rank sum test, P=0.02; Figure 1A and 
Table 1 in Ref. III). The substantial difference in the cumulative span of CNVs 
was caused by 3–10-fold decrease in the number of duplications in the RPL 
placental samples compared to controls. As mentioned above, among term 
complications the lowest mean number of placental CNVs was identified in the 
small-for-gestational age group; however, in the RPL placentas it was almost 
twofold further reduced (18.3 vs. 10.0 CNVs, respectively; Figure 17). These 
results point to a common aspect of all pregnancy complications – lack of 
somatic structural variation in the placental genome that may impair early 
trophoblast development. Surprisingly, three live birth placental samples from 
RPL couples also carried a limited amount of CNVs like pregnancy loss 
samples (Figure 17).  
Placental genomic rearrangements were clustered into CNV regions 
(CNVRs, at least two rearrangements of the same type (deletion or duplication) 
overlapping with 40% coverage) and RPL samples were compared with normal 
1st trimester and term pregnancy groups. Normal 1st trimester placental samples 
shared 35.1% (n=46/131) of CNVRs with term placentas, while only 5.3% 
(n=7/131) of rearrangements coincided with RPL samples (Fisher’s exact test, 
P=1.1 × 10–9; Figure 1B in Ref. III).  
 
 
Figure 17. Number of all autosomal CNVs in the placental samples of RPL cases 
compared to controls representing normal 1st trimester, normal term pregnancy and late 
pregnancy complications. Placentas from RPL couples eventually succeeding in a term 
live birth after a successful pregnancy are indicated with green diamonds. 
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Interestingly, 8 CNVRs that were shared or encompassed the same gene 
between RPL and control samples were alternatively rearranged in pregnancy 
loss placentas (Table 2 in Ref. III). For example, two control placentas carried 
duplications involving the whole MTRR (methionine synthase reductase) gene, 
but the duplication in RPL placenta disrupted the gene (Figure 2 in Ref. III). 
MTRR is essential for utilization of methyl groups from the folate cycle to 
activate methionine synthase, necessary for methionine synthesis (Shane and 
Stokstad, 1985) and further generation of S-adenosylmethionine (SAM). SAM 
acts as a methyl donor for loads of cellular substrates, including DNA, RNA 
and proteins (Kusakabe et al., 2015). Mtrr deficiency has been shown to have 
transgenerational effect through epigenetic markers, causing growth defects and 
congenital malformations in mice (Padmanabhan et al., 2013). The folate-
methionine cycle certainly has an important role in early embryonic develop-
ment. Three control placental genomes carried CNVs in CTNNA3 gene, which 
were distinct from the maternally inherited deletion identified in the RPL 
placenta (Table 2 in Ref. III). As described above, a maternally transmitted 
deletion at the same locus was detected in an independent study of recurrent 
miscarriage samples (Figure 2 in Ref. III) (Rajcan-Separovic et al., 2010). In 
our previous study of late pregnancy complications, I detected no deletions, but 
somatic duplications in two GDM, one PE, and one SGA placenta (Ref. II, 
Table 7). Further confirming its role in early fetal development, a fetus with 
syndromic malformations was recently reported to carry 180 kb microdeletion 
in the CTNNA3 gene (Cancemi et al., 2016). CTNNA3 is highly expressed in the 
placenta during the first trimester and shows cell-type specific genomic im-
 
 
3.3.2 Functional pathway analysis of placental CNVRs specific to  
RPL cases and controls 
Functional enrichment analysis of genes located within the CNVRs unique to 
RPL placental samples revealed enrichment of only polymorphic olfactory 
receptor loci (Suppl. Table S3 in Ref. III). However, analysis of the CNVRs 
specific to controls highlighted enrichment of binding sites for multiple 
transcription factors (TF) relevant to placental and fetal development (Figure 
18). Over 70% of the query genes (n=630) showed binding motifs for ZF5 and 
E2F transcription factors. Supportive to this finding, another study from our 
group found that almost two-thirds of differentially expressed genes in RPL 
placental samples compared to controls have binding sites for E2F transcription 
factors (Sõber et al., 2016).  
printing with biallelic expression in extravillous trophoblast and monoallelic 
expression of the maternal allele in villous trophoblast (van Dijk et al., 2004). 
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Figure 18. Functional enrichment analysis of genes within the CNVRs exclusively 
detected in the placental genomes of normal 1st trimester and term pregnancies. TFBS, 
transcription factor binding site. 
Not much is known about the function of ZF5, but E2F activator and repressor 
proteins orchestrate the mammalian endoreplication process which refers to 
multiple genome amplifications in the absence of cell division/cytokinesis 
(Chen et al., 2012). Mice embryos deficient of E2f7/E2f8 have been shown to 
display overall smaller placentas and severely compromised tissue architecture, 
and also fetal growth retardation and midgestation lethality (Ouseph et al., 
2012). Furthermore, loss of atypical E2Fs (E2F7/8) causes severe vascular 
defects during embryonic development in zebrafish and mice via transcriptional 
regulation of VEGFA (Weijts et al., 2012), indicating an important role in 
angiogenesis. Strikingly, the same group discovered that loss of these E2Fs in 
cancer cells actually promotes angiogenesis and branching of tumor blood 
vessels (Weijts et al., 2017). TFAP2A, the regulator of placental CGB ex-
pression (Glodek et al., 2014), has been recently proposed as one of the earliest 
drivers of trophoblast specification in human embryonic stem cells (Krendl et 
al., 2017). Additionally, GKLF has been reported as a potential regulator of 
Pregnancy-specific glycoproteins (PSGs) (Blanchon et al., 2001), the most 
abundant placental proteins in maternal blood during human pregnancy (Moore 
and Dveksler, 2014). Rearrangements of genes containing binding sites for 
critical TFs involved in the regulation of intrauterine development could 
represent an alternative mechanism to activate or repress genes at specific time 
points. 
Most of the genetic studies regarding RPL have focused on maternal 
genomes; however, an ideal study would include the analysis of both parents as 
well as miscarried conceptuses (placental samples) and liveborn children. Our 
seminal study of CNVs in recurrent pregnancy loss included only parental 
genomes (Ref. I), but the availability of placental samples from different stages 
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of normal gestations and pregnancy loss in this study gave us an excellent 
resource to discover possible novel biomarkers and pathways important in early 
in utero development. 
 
 
3.3.3 A closer look at the parental and placental CNV profiles of  
the three live birth RPL cases 
The number of CNVs in RPL live birth placentas was as low as in pregnancy 
loss samples; however, the rearranged regions involved genes also duplicated in 
normal term placentas. A 42% overlap in respective gene content was detected, 
compared to only 25% with miscarriage samples. This may have supported the 
successful maintenance of these index pregnancies. Additionally, in two of the 
three families, either one (RPL3) or both or the parents (RPL11) carried large 
pericentromeric CNVs (0.3–0.6 Mb/genome; Suppl. Table S5 in Ref. III), which 
were not transmitted to the successful pregnancy placentas. 
In one of the families (RPL3), two successful pregnancies preceded the 
index live birth. As described above, the number of live births showed negative 
correlation with the number of placental CNVs in normal term pregnancies. 
Interestingly, the index babies born to the other two families were firstborn and 
large-for-gestational age (LGA; RPL11: male 4,488 g, RPL12: female 5,060 g; 
Suppl. Data S1 in Ref. III). Moreover, both couples had primary RPL (no live 
births before three consecutive pregnancy losses), had further losses after the 
index case and another successful pregnancy resulting again in LGA newborns 
(RPL11: male 4,990 g, RPL12: female 4,590 g). I propose that there are 
compensatory mechanisms that allow for the overcoming of early pregnancy 




3.3.4 Major contribution of this study to the field of  
placental and RPL research  
1. This study confirmed our hypothesis that RPL placental genomes carry a 
reduced amount of CNVs, possibly affecting normal trophoblast develop-
ment and pregnancy success. 
2. Alternative rearrangements of certain genes (e.g. CTNNA3, MTRR) were 
detected in RPL placentas compared to normal pregnancies, which may 
confer risk to pregnancy loss. 
3. Uncovering the role of specific transcription factors (E2F, AP2, KLF4 and 
ZF5) involved in the process of placental and fetal development in 





4. EXTENDED DISCUSSION AND FUTURE PERSPECTIVES 
4.1 Load of structural variants in the placenta –  
harm or benefit? 
During normal cell division, the genome is completely duplicated and after that 
segregated to two daughter cells. However, in some tissues the cells duplicate 
their genome without disassembling cellular and nuclear membranes, resulting 
in polyploidy. Polyploidy can be achieved by endoreplication, which is 
comprised of DNA synthesis and gap phases without mitosis (Fox and Duronio, 
2013). As an example, around 50% of human hepatocytes are normally poly-
ploid, suggesting that endoreplication is necessary for normal liver function to 
manage stress and injuries (Duncan, 2013). Gene amplification can be triggered 
by developmental signals. Polyploid Drosophila follicle cells, for example, 
require several copies of the chorion genes in order to produce enough protein 
for normal eggshell formation (Calvi and Spradling, 1999). Murine trophoblast 
giant cells (TGC) are also known to be polyploid and exhibit repressed mitotic 
machinery similar to Drosophila endocycling cells (Sher et al., 2013).  
In our seminal study (Ref. II) of CNVs in the human placental genome, an 
extensive load of duplications was found characteristic for normal pregnancy 
placental samples. Hannibal et al. have thoroughly demonstrated the variable 
nature and flexibility of murine placental genome in two reports (Hannibal and 
Baker, 2016; Hannibal et al., 2014). Their seminal study showed that specific 
regions of the TGC genome are under-replicated and enriched for genes 
involved in cell adhesion and neurogenesis. I compared the somatic placental 
CNVs (Ref. II) with their data and found five recurrent CNV regions in the 
human placenta overlapping with respective syntenic regions in murine 
placental polyploid TGCs described with decreased copy number, involving the 
genes EPHA7, CSMD3, COL11A1, DPYD and GRIK2 (Suppl. Table 8 in Ref. 
II). In their latest article, Hannibal et al., 2016 reported selective amplification 
of prolactins, serpins, cathepsins, and the NK/CLEC complex in the mouse 
placenta. All these gene families encode genes that are crucial for murine early 
pregnancy. Rodents have undergone extensive tandem amplifications of the 
cathepsin and prolactin gene families and these regions represent a hotspot for 
additional rearrangements. Humans have only one prolactin gene and several 
scattered serpin, cathepsin, and CLEC genes located all over the genome. I did 
not discover any duplications in these genes, although I did find amplifications 
of genes that interact with several SERPIN, cathepsin (CTS) and CLEC pro-
teins. In humans, most of these genes are not placenta-specific but are expressed 
in various tissues. These observations suggest that while the somatic rearrange-
ments seem to be a characteristic feature of placental genomes in mammals, the 
respective hotspots and involved genes may differ due to local genomic struc-
ture or the ‘necessity’ to promote amplification of lineage-specific placental 
genes. 
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Functional pathway analysis of CNVRs detected exclusively in normal 
pregnancy placentas compared to recurrent pregnancy loss samples revealed 
enrichment for genes that have binding sites for E2F transcription factors. E2Fs 
control the expression of genes required for DNA synthesis and cell cycle (Fox 
and Duronio, 2013). Conversely, the embryonic development and cell cycle 
related pathways were enriched in the copy number stable map (most dosage-
sensitive regions) of the human genome (Zarrei et al., 2015). While most human 
tissues may be void of rearrangements in these regions, because there is no need 
for such rapid and precocious development as in the case of placenta, functions 
related to cell cycle, growth, and adhesion are preferably reorganized also in 
cancer genomes (Koutsogiannouli et al., 2013).  
A recent report on the genomic profile of choriocarcinoma (gestational 
trophoblastic disease) did not find major overlap with our CNV data in normal 
placentas; however, loss of 18q22.1 involving CDH19 gene was detected in 
four gestational choriocarcinoma samples (Mello et al., 2017). On the contrary, 
I found duplications in the same gene in three 2nd trimester normal pregnancy 
samples and one SGA placenta. Thus, differential rearrangement and possibly 
expression of this gene may play a role in both normal placental development as 
well as cancer progression. A recent study has shed light on how copy gain can 
be induced and that it is not always permanent. Black et al. demonstrated that 
hypoxia stimulates transient site-specific copy number alterations (also seen in 
hypoxic primary tumors) dependent on chromatin modulation (Black et al., 
2015). Hypoxia is a common phenomenon in a majority of malignant tumors 
besides early placental development (Fajersztajn and Veras, 2017; Muz et al., 
2015). There is a definite need for interdisciplinary studies in research areas 
regarding placental and cancer development in order to find out the exact 
mechanisms behind CNV formation and function. 
 
 
4.2 Placental CNVs and non-invasive prenatal testing 
Noninvasive prenatal testing (NIPT) by maternal plasma DNA sequencing has 
been in use since 2011 to screen for common fetal aneuploidies. The circulating 
cell-free DNA reflects maternal (~85–90%) and fetoplacental DNA (Wang et 
al., 2013). The specificity and sensitivity of NIPT has become high over the 
years; however, discordant results still remain (Hartwig et al., 2017). These 
could be due to confined placental mosaicism, true fetal mosaicism, maternal 
pathology or presence of a deceased twin. Recently, maternal incidental fin-
dings (e.g. B12 deficiency, autoimmune disease, tumors) have been suggested 
as the main cause of false-positive and false-negative sequencing results 
(Bianchi, 2017). Based on this review, before invasive fetal diagnostic pro-
cedure is performed, maternal peripheral blood karyotype should be analyzed. If 
maternal abnormalities can be ruled out, invasive diagnostic (chorionic villus 
sampling or amniocentesis) testing is still needed to verify true fetal ab-
normality. 
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Most of the present NIPT methods provide information only about trisomies 
13, 18 and 21. However, some centers also apply genome-wide algorithms and 
look for subchromosomal abnormalities besides aneuploidies (Brison et al., 
2017; Lefkowitz et al., 2016). Brison et al. reported recurrent CNVs (<500 kb) 
associated with developmental disorders and adult-onset conditions in ~0.4% of 
samples. Such approaches may provide more clinically important results, but on 
the other hand lead to the identification of fetal/maternal variants of unknown 
significance that complicates counselling. As the methods opt for higher 
resolution and detect smaller rearrangements, it is important to consider the 
extensive somatic genomic rearrangements and mosaicism in the placenta that 




4.3 Importance of CNV profiling in the clinical management 
of pregnancy complications 
Firstly, the current thesis has demonstrated that large genomic rearrangements 
in the parental genomes predispose towards poor pregnancy outcomes. In 
addition to classical karyotyping, chromosomal microarray analysis should be 
recommended for couples in order to identify large submicroscopic and 
pericentromeric CNVs, and overall load of CNVs as risk factors for RPL. 
Parental genetic testing in couples with RPL is currently not recommended by 
ESHRE; however, it may help in the early detection of cases at risk and provide 
close monitoring in their subsequent pregnancies, as well as suggest available 
prenatal testing options.  
Secondly, the ultimate goal of the analysis of structural variants would be the 
discovery of specific diagnostic CNVs leading to the possibility of targeting 
gene products deleted/duplicated in particular pregnancy complications. 
Although cancer is a different phenotype, an excellent example of a trackable 
biomarker in cell-free DNA from blood was recently published (Goh et al., 
2017). We have discovered a common duplication at 5p13.3 that could be a 
pleiotropic risk factor for recurrent pregnancy loss as well as preeclampsia; 
however, it is not very likely to find recurrent CNVs that cause gestational 
complications; rather every case carries its own (combination of) risk variants. 
The detection of specific submicroscopic rearrangements as a diagnostic 
method in pregnancy complications requires a great deal of further investi-
gation. At the moment, family-based studies are justified in research to identify 
the cause of a specific pregnancy loss event as an example, and to define 
segregation of the discovered causal CNV in the given family.  
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Thirdly, microarray-based CNV analysis of products of conception (POC) 
should be recommended to couples with RPL. A 24-chromosome microarray 
evaluation of miscarriage tissue has recently proven to be very cost-effective 
and time-efficient (Popescu et al., 2018). This may provide a definitive cause 
for the specific miscarriage in a majority of cases, prognosis for subsequent 
pregnancy success, and estimation and/or prevention of having a child with 
birth defects. It would lead to better clinical diagnoses, improve counselling of 
couples, and thereby exclude unnecessary analyses and save costs to the health-





The current doctoral thesis project unravelled a small fraction of the enormous 
puzzle of the profile and role of CNVs in human gestational complications and 
placental genomes of normal and disturbed pregnancies. The results of this 
thesis can be summarized as follows: 
1. Genome-wide CNV profiling of parental genomes of couples with recurrent 
pregnancy loss confirmed the role of structural variation in modulating the 
genetic susceptibility to RPL, and may provide new biomarkers for multiple 
gestational complications. 
2. Extensive load of CNVs was detected as a hallmark of normal placental 
development. Early as well as late pregnancy complications showed reduced 
capacity to promote somatic genomic rearrangements in the placenta. 
3. CNVs detected exclusively in normal pregnancy placentas compared to RPL 
samples were shown to be enriched in genes regulated by transcription 
factors critical in early embryonic development, and the regulation of basic 
cellular processes, such as E2F, ZF5, KLF4, AP2, and SREBP. In perspec-
tive, these pathways represent a potential source for new biomarkers for the 
evaluation of fetal health and early detection of pregnancy complications. 
The material presented here serves as a great resource of CNV data for future 
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SUMMARY IN ESTONIAN 
Genoomi struktuursed varieeruvused platsenta ja 
raseduse mõjutajatena 
Ema ja loote vaheline suhtlus loob aluse raseduse edukaks kulgemiseks, sünni-
tuseks ning ka sünnitusjärgseks ajaks. Rasedus on naise jaoks füsioloogiline 
väljakutse, mida kinnitab fakt, et inimese viljakuse efektiivsus on madal, 
ligikaudu 30% kõigist viljastatud munarakkudest ei pesastu emakasse. Spon-
taanne raseduse katkemine on kõige sagedasem rasedusaegne tüsistus. 40% 
rasedustest hakkavad emaka sees küll arenema, kuid nendest 30% juhtudel 
toimub katkemine väga varajases etapis (nn biokeemiline rasedus) ja 10% 
juhtudest on tegemist kliinilise raseduse katkemisega (ultraheliuuringuga tuvas-
tatav). Korduv raseduse katkemine (KRK), defineeritud kui ≥3 järjestikust 
raseduse katkemist enne 24-ndat gestatsiooninädalat, esineb 1–2% kõigist last 
saada üritavatest paaridest. KRK-d võivad põhjustada anatoomilised, infekt-
sioossed, endokriinsed, immuunsüsteemiga seotud põhjused ning geneetilised 
faktorid, kuid 25–50% juhtudest on siiski põhjus selgusetu. 
Rasedusaegsed füsioloogilised muutused põhjustavad osadel naistel hiliseid 
rasedustüsistusi nagu preeklampsia, gestatsioonidiabeet ning raseduskestuse 
kohta väike ja suur sünnikaal, mis võivad omakorda naise organismis paljastada 
eelsoodumuse mitmetele kroonilistele haigustele (diabeet, südame-veresoon-
konna haigused). Lisaks on häired üsasiseses arengus riskifaktoriks erinevatele 
haigustele ka lapse tulevases elus. Eelmainitud gestatsiooniaegseid komplikat-
sioone, mis mõjutavad naisi ja lapsi üle kogu maailma, on sageli seostatud 
puuduliku trofoblasti invasiooni ning platsenta funktsiooniga. Seetõttu on 
äärmiselt oluline täielik arusaam platsenta bioloogiast, arengust ja funktsioonist. 
Platsenta, ainus ‘lühiajaline’ organ, vahendab kõiki interaktsioone ema ja loote 
vahel, kuid paraku ei ole seda veel piisavalt põhjalikult uuritud nii eetilistel kui 
ka metodoloogilistel põhjustel. Platsenta geenide avaldumise tase ja dünaamika 
reguleerib platsenta funktsiooni ja seeläbi raseduse kulgemist. Inimese platsenta 
transkriptoomi moduleerib geneetiline varieeruvus, millest kõige enam on 
uuritud ühenukleotiidseid muutusi. 
DNA koopiaarvu varieeruvused (copy number variation, CNV) on >50 bp 
ümberkorraldused, mis moodustavad ligikaudu 10% inimese genoomist. CNV-d 
võivad olla tingitud üht või mitut geeni või DNA piirkonda hõlmavatest delet-
sioonidest ja duplikatsioonidest. Need struktuursed variandid annavad oma osa 
genoomi normaalsele varieeruvusele, kuid samas soodustavad mõned ümber-
korraldused erinevate haiguste teket. CNV-d võivad mõjutada (varajases) 
embrüonaalses arengus oluliste geenide doosi otseselt (kogu geeni hõlmav 
duplikatsioon või deletsioon) või kaudselt (regulatoorsete elementide ümber-
korraldused). CNV-de seost reproduktiivhäiretega on siiani vähe uuritud. 
Platsenta ja vanemate genoomi struktuuri mõistmine nii normaalse raseduse kui 
ka rasedusaegsete tüsistuste puhul võimaldab tuvastada biomarkereid, mille 
eesmärk oleks ennustada raseduse kulgu/lõpptulemust.   
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Käesoleva doktoritöö kirjanduse ülevaates on tutvustatud platsenta arengut 
ja funktsiooni, varaseid (KRK) ja hiliseid (preeklampsia, gestatsioonidiabeet, 
raseduskestuse kohta väike/suur sünnikaal) rasedusaegseid komplikatsioone, 
nende riskitegureid ja geneetilist tausta. Lisaks on kirjeldatud DNA koopiaarvu 
varieeruvusi, nende tuvastamise meetodeid ning võetud kokku tänaseks 
avaldatud info koopiaarvu varieeruvuste rollist rasedustüsistuste kujunemisel.  
Doktoritöö eksperimentaalses osas on püstitatud järgmised eesmärgid: 
I. Tuvastada korduva raseduse katkemisega paaridel üldlevinud CNV-sid kui 
uusi KRK geneetilisi markereid ning leida uusi lookuseid ja bioloogilisi 
radasid, mis mõjutavad raseduse kulgu. 
II. Võrrelda kogu genoomi CNV-de profiili vanemate verest eraldatud ja 
platsentast eraldatud DNA-s nii normaalse raseduse erinevatel trimestritel 
kui rasedustüsistuste korral.  
III. Kirjeldada võrdlevalt submikroskoopiliste genoomsete ümberkorralduste 
profiili samas raseduse kestuses KRK-ga platsentades ja normaalselt kulge-
nud raseduse platsentades.  
Doktoritöö peamised tulemused on: 
1. KRK paaridel esinevad CNV-d hõlmavad oluliselt enam geene, mis päri-
nevad immuunvastuse väljakujunemisega seotud bioloogilistest radadest. 
See leid kinnitab immuunsüsteemi olulist rolli varajase raseduse säilitamisel. 
2. KRK patsientidel on CNV-de koguulatus ning pikkade deletsioonide osakaal 
genoomi kohta suurem võrreldes viljakate kontrollidega. Laialdane CNV-de 
esinemine genoomis võib hõlmata olulisi geene varajaseks arenguks ning 
soodustada omakorda ümberkorralduste teket gametogeneesis ning rakkude 
jagunemisel varajases embrüonaalses arengus. Lisaks leidub KRK vanemate 
genoomides enam pikki peritsentromeerseid ja subtelomeerseid CNV-sid, 
mis soosivad vigu kromosoomide normaalsel jagunemisel. 
3. Üldlevinud CNV piirkondade uuring Eesti ja Taani valimites tuvastas dupli-
katsiooni 5p13.3 kromosoomi piirkonnas, mis suurendab KRK riski naistel. 
Antud CNV hõlmab kahte platsentas kõrgelt avaldunud geeni (PDZD2 ja 
GOLPH3), mida pole varasemalt rasedusega seostatud. 
4. CNV-de genoomne kaardistamine duo/trio uuringus tuvastas submikroskoo-
piliste ümberkorralduste suure hulga platsentas võrreldes vanemate genoo-
midega. Eelkõige oli CNV-de rohkus tingitud duplikatsioonide arvust. Nen-
des esinevate geenide funktsionaalse rikastatuse analüüsist ilmnes, et ümber-
korraldused asuvad geenides, mis on olulised just embrüonaalses arengus. 
5. Nii varaste kui hiliste rasedustüsistuste puhul esines CNV-sid platsentas 
oluliselt vähem kui normaalselt kulgenud raseduste proovides, viidates 
CNV-de kriitilisele rollile raseduse edukal kulgemisel. 
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6. Somaatilistes (ainult platsenta koes esinevates, mitte vanematelt päritud) 
duplikatsioonides tuvastati vermitud geenide rikastatus. Selle puhul võib 
tegu olla geenide avaldumise regulatsiooni lisatasandiga, mis tuleks välja 
selgitada edasistes uuringutes. 
7. KRK ja kontrollide platsentas esinevate CNV-de võrdlusest tuvastati alter-
natiivsed ümberkorraldused, mis hõlmasid mõlemas grupis küll samu geene 
(näiteks CTNNA3, MTRR), kuid erinesid genoomse ümberkorralduse ulatuse 
või asukoha suhtes. Ühe geeni eri piirkondi hõlmavad CNV-d võivad omada 
erisugust efekti ning mõjutada KRK riski. 
8. Üksnes normaalse I ja III trimestri platsentades esinevate CNV-de (võrreldes 
KRK platsenta genoomi CNV profiiliga) geenide funktsionaalse rikastatuse 
analüüs näitas, et genoomsed ümberkorraldused mõjutavad geene, mis on 
reguleeritud teatud transkriptsioonifaktorite (näiteks E2F, AP2, KLF4) poolt. 
Edasised uuringud näitavad, kas tuvastatud faktoreid oleks võimalik 
tulevikus kasutada rasedustüsistuste varajasel prognoosimisel ja/või ravis. 
Doktoritöös analüüsiti esmakordselt kogu genoomi CNV-de profiili KRK paa-
ride genoomis. Hüpoteesi-vaba lähenemine võimaldas leida uusi lookusi seoses 
KRK-ga ning kinnitas struktuursete varieeruvuste rolli raseduse katkemise 
etioloogias. 
Lisaks viidi läbi ka esimene duo/trio uuring (platsenta-ema-isa), et kirjeldada 
genoomi struktuursete ümberkorralduste profiili normaalse raseduse kolmel 
trimestril ning hiliste rasedusaegsete tüsistuste korral. Töö üheks olulisemaks 
sõnumiks on see, et normaalse platsenta arenguks on vajalik oluliselt suurem 
CNV-de hulk kui seda on muudes mittemaliigsetes rakkudes. 
Kuna platsenta funktsioon mõjutab loote ja ema tervist oluliselt nii raseduse 
vältel kui ka edasises elus, siis on platsenta genoomi uurimine äärmiselt oluline, 
paljastamaks täpsed mehhanismid, misläbi oleks tagatud edukas rasedusaegne ja 
-järgne periood. Käesoleva uurimistöö materjal on suurepäraseks CNV andmete 
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